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ABSTRACT 
Our immune system protects us from infectious agents and sustains the homeostasis in our 
body. However, the immune system can also play a role in initiation and progression of diseases 
such as autoimmune diseases and cancer. Cancer is still one of the leading causes for death 
worldwide and inflammation became one of the hallmarks of cancer. Besides carrying out anti-
tumor immune responses, the immune system also supports tumor growth through different 
aspects, such as promoting vascularization and suppressing other immune cells. Thus, targeting 
the immune system and harnessing its potential for anti-cancer therapy is a promising approach 
for treating cancer patients. Especially tumor-associated macrophages (TAMs) have shown to 
exert many tumor-supporting properties and represent a predominant immune cell population 
in most of the tumors. Therefore, the focus of this thesis was to evaluate the role of scavenger 
receptor MARCO on macrophages in immune responses and to reveal its potential as target for 
cancer immunotherapy. 
Paper I identifies a novel interaction between marginal zone macrophages (MZMs) and 
marginal zone B cells (MZBs) that regulates antigen (Ag) transport into the follicle and Ag 
deposition onto follicular dendritic cells (FDCs) in the spleen. This can be modulated by 
targeting MARCO on MZMs by monoclonal antibodies (Abs) which leads to less Ag shuttling 
into the follicle, decreased Ag deposition to FDCs and to a subsequent reduced adaptive 
immune response. Anti-MARCO Abs can also be found in human system lupus erythematosus 
patients and this study may clarify the reason for their increased susceptibility for infections. 
Paper II reveals MARCO as novel marker for a distinct tumor-promoting macrophage subtype 
in melanoma, breast and colon cancer mouse models. Anti-MARCO Ab treatment leads to 
reduced tumor growth and metastases and reprograms the MARCO+ immune suppressive 
TAMs towards a pro-inflammatory phenotype. The combination of anti-MARCO Abs with 
checkpoint inhibitor anti-CTLA-4 shows enhanced efficacy and suggests MARCO targeted 
therapy as a promising cancer immunotherapy approach. Moreover, MARCO expressing 
TAMs can also be found in human breast cancer and melanoma patients. 
Paper III investigates the mechanism of how anti-MARCO Ab treatment leads to reduced 
tumor growth in melanoma: Targeting MARCO by Abs leads to the activation of natural killer 
(NK) cells to increase their TRAIL-dependent tumor cell killing. MARCO+ TAMs display a 
perivascular macrophage phenotype and targeting MARCO not only leads to metabolic re-
programing of the MARCO+ TAMs but results also in less confuse tumor vascularization. We 
confirmed enhanced efficacy of anti-MARCO Abs in combination with checkpoint inhibitors 
anti-PD-1 or anti-PD-L1 Abs and produced anti-human MARCO (hMARCO) Abs by 
immunizing mice with human MARCO protein to translate our findings to humans. Co-culture 
experiments with human MARCO+ macrophages and T cells or NK cells validate that targeting 
hMARCO by Abs re-activates the effector cells leading to increased activation, proliferation 
and human melanoma cell killing in vitro. 
Paper IV studies MARCO expression on immune suppressive myeloid cells in human 
pancreatic ductal adenocarcinoma patients, a cancer type with very poor prognosis. MARCO 
expression is induced by tumor-derived IL-10 and under hypoxic conditions not only found on 
immune suppressive TAMs but also on myeloid derived suppressor cells. Targeting MARCO+ 
myeloid cells by anti-human MARCO Ab restores cytotoxic anti-tumor activity of T cells and 
NK cells including increased activation, proliferation and human pancreatic cancer cell killing 
in vitro. 
Altogether, the work presented in this thesis gives us new insights into the biology of scavenger 
receptor MARCO, increases our understanding of the tumor microenvironment and how we 
can re-activate macrophages and modulate the immune suppressive tumor microenvironment 
by monoclonal Abs. Targeting MARCO enhances anti-tumor responses and the cytotoxicity of 
effector cells making it a promising approach for further immunotherapies. Our findings 
contribute to the design of new anti-cancer therapies including combining other 
immunotherapies with anti-MARCO Ab. 
  
  
ZUSAMMENFASSUNG 
Das Immunsystem ist unser Abwehrsystem, welches uns vor Krankheitserregern und 
Infektionen schützt, das Gleichgewicht im Körper aufrecht erhält und somit 
Autoimmunerkrankungen und Gewebeschädigungen verhindert. Das Immunsystem besteht 
aus verschiedenen Immunzellarten, die auch als weiße Blutkörperchen bekannt sind. Sie 
kommunizieren miteinander und beschützen uns gemeinsam vor eindringenden Erregern und 
entarteten Zellen. Die Immunzellart, die für diese Thesis von besonderer Bedeutung ist, ist der 
Makrophage. Makrophagen sind Fresszellen, die Krankheitserreger direkt aufnehmen und 
zersetzen können oder aber andere Immunzellen durch die Produktion von Immunmodulatoren 
zum Ort der Entzündung rufen. Sie sind in allen Organen vorhanden und zirkulieren durch 
unsere Gefäße, um die Umgebung nach Fremdkörpern ab. Neben dem “Fressen” von 
Pathogenen, vernichten Makrophagen auch körpereigene Zellen, die zu alt sind, sterben oder 
Unregelmäßigkeiten aufweisen. Diese Zellen stellen ein potentielles Risiko dar und könnten 
durch Entartung zur Krebsentstehung beitragen.  
Krebs ist noch immer eine der tödlichsten Krankheiten weltweit und es wurde bewiesen, dass 
eine Entzündung im Körper die Tumorentstehung begünstigen und das Immunsystem dabei 
sogar eine unterstützende Rolle spielen kann. Somit sind Immunzellen bei der 
Tumorbekämpfung ein zweiseitiges Schwert: Zum einen hat das Immunsystem eine anti-
tumorale Wirkung. Am Anfang, wenn sich entartete Tumorzellen vermehren, werden unsere 
Abwehrzellen durch Immunmodulatoren gerufen, um den Tumor zu eliminieren. Diese 
Immunmodulatoren werden sowohl von gewebseigenen Zellen als Gefahrsignal als auch von 
Tumorzellen selbst ausgeschüttet und weisen den Immunzellen den Weg. So werden 
Abwehrzellen rekrutiert, die anfangs aktiv gegen die Tumorzellen vorgehen. Zum anderen sind 
Tumorzellen schlau und überlisten leider oft genug das Immunsystem, welches sie gezielt 
wissen “umzupoolen”, damit es dem Tumor dann beim Wachstum hilft. Dies geschieht durch 
verschiedene Stoffe, die der Tumor ausschüttet um eine immun-unterdrückende Umgebung zu 
schaffen, welche die Immunzellen vom aktiven Bekämpfen der Tumorzellen abhält. Auch neu 
eintreffende Immunzellen werden so ”ausgeschaltet” und der Tumor kann wachsen ohne vom 
Immunsystem bekämpft zu werden. Es ist sogar bekannt, dass Immunzellen den Krebszellen 
beim Metastasieren helfen und ihnen Zutritt zu den Lymph- und Blutgefäßen gewähren.  
Da Immunzellen in so gut wie allen Tumorarten vorkommen und dabei aber leider meist tumor-
unterstützend agieren, haben Wissenschaftler in den letzten Jahren daran gearbeitet, diese 
ausgeschalteten Abwehrzellen zu re-aktivieren, damit sie die Krebszellen erfolgreich 
bekämpfen können. Das hat den Wissenschaftlern James P. Allison und Tasuku Honjo im Jahr 
2018 den Nobel Preis der Medizin gebracht. Sie waren die ersten, die herausgefunden haben, 
wie man die ”Bremse” von einzelnen Immunzellen löst. Diese re-aktivierten Immunzellen 
können dann wieder verstärkt gegen Tumorzellen vorgehen, was dann zu einer Verkleinerung 
der Tumore und oft sogar zu kompletter Heilung führt. Leider sprechen nicht alle Patienten auf 
diese Art von Krebstherapie an, der Grund dafür ist bislang noch unbekannt. Deshalb arbeiten 
Wissenschaftler auf der ganzen Welt noch immer daran weitere Moleküle/Ziele auf 
Immunzellen zu finden, welche man für die Krebs-Immuntherapie nutzen und eventuell auch 
in Kombination mit anderen Therapieansätzen anwenden kann, z.B. mit einer Chemotherapie.  
Die hier vorliegende PhD Arbeit beschäftigt sich hauptsächlich mit tumor-assoziierten 
Makrophagen, welche häufig in großen Zahlen in Tumoren vorkommen, dabei meistens pro-
tumoral sind und das Tumorwachstum unterstützen. In dieser Thesis untersuche ich die Rolle 
von dem Rezeptor MARCO, der auf der Außenseite von Makrophagen zu finden ist, in 
Immunantworten aber auch in Bezug auf Tumore. Die zentrale Frage dabei ist: Ist MARCO 
ein potenzielles Ziel für Krebs-Immuntherapien? 
Artikel I beschäftigt sich mit der Interaktion zwischen den MARCO+ Makrophagen und den 
B Zellen in der Milz. B Zellen sind die Immunzellen im Körper, die für die 
Antikörperproduktion zuständig sind und die Milz ist der Ort, an dem wichtige Prozesse für 
den Start einer Immunantwort stattfinden. Die Milz filtert das Blut des Körpers und die 
Immunzellen scannen es auf potenzielle Krankheitserreger, die sie dann aus dem Blut 
herausfangen, eliminieren und dann abhängig vom Pathogenen eine spezifische 
Immunreaktion einleiten. In unserer Studie haben wir herausgefunden, dass die Immunreaktion 
verändert wird, wenn man Mäusen Antikörper intravenös spritzt, die den Rezeptor MARCO 
spezifisch erkennen und binden. Wir haben die Interaktion zwischen den MARCO+ 
Makrophagen und den B Zellen in der Milz so modifiziert, dass die B Zellen weniger Antigen 
transportieren und im Endeffekt auch weniger spezifische Antikörper herstellen. Patienten, die 
an der Autoimmunerkrankung systemischer Lupus erythematodes leiden, haben auch 
Antikörper gegen MARCO in ihrer Blutlaufbahn, von denen man aber nicht genau weiß was 
ihre Aufgabe ist. Unsere Ergebnisse könnten eine Erklärung für ihr erhöhtes Infektionsrisiko 
sein. 
In Artikel II zeigen wir zum ersten Mal in drei verschiedenen Maus-Tumormodellen, dass 
MARCO ein Marker für die pro-tumoralen und immun-unterdrückenden tumor-assoziierten 
Makrophagen ist: Genauer gesagt in Brustkrebs, Hautkrebs und Darmkrebs. Wenn wir diese 
Mäuse mit anti-MARCO Antikörpern behandeln, haben sie kleinere Tumore und auch weniger 
Metastasen in der Lunge. Mithilfe der Antikörper-Behandlung können wir diese pro-tumoralen 
Makrophagen um-programmieren und re-aktivieren, um die Krebszellen zu bekämpfen. Auch 
die Kombination von unseren anti-MARCO Antikörpern und den bereits in Menschen 
genutzten Immuntherapie, welche auf dem Molekül CTLA-4 basiert und von Nobelpreis-
Träger James P. Allison entdeckt wurde, ist vielversprechend: In der Kombination sehen wir 
noch kleinere Tumore verglichen zu den einzelnen Behandlungen. Um unsere Entdeckung in 
Zukunft auch beim Menschen anwenden zu können, wollten wir wissen, inwiefern MARCO 
in humanen Tumoren verbreitet ist. Tatsächlich haben wir MARCO auf pro-tumoralen 
Makrophagen in mehreren humanen Tumorarten gefunden, z.B. in Brustkrebs und Hautkrebs. 
Deshalb glauben wir, dass eine anti-MARCO gerichtete Therapie eine wirklich 
vielversprechende Art der Krebs-Immuntherapie ist.  
In Artikel III beschäftigen wir uns mit dem Mechanismus, warum das Spritzen von anti-
MARCO Antikörpern zu kleineren Tumoren führt. Wie funktioniert das Ganze? Was genau 
passiert in den Makrophagen? Und sind die Makrophagen alleine für die Tumorreduktion 
  
verantwortlich? In diesem Artikel beschäftigen wir uns nur mit Hautkrebs als Modell und 
sehen, dass die Umprogrammierung der Makrophagen viele intrazelluläre Prozesse beinflusst 
und auch den kompletten metabolischen Haushalt der Zelle verändert. Interessanterweise re-
programmiert die auf MARCO zielende Immuntherapie nicht nur die Makrophagen, sondern 
aktiviert auch andere Immunzellen im Tumor, die natürliche Killerzellen (NK Zellen) genannt 
werden. Diese NK Zellen können Krebszellen direkt töten, indem sie mit ihnen in Kontakt 
treten und mithilfe von Rezeptoren-Verbindungen den Tod der Tumorzelle induzieren oder 
aber ”Killer-Substanzen” ausstoßen, die die Tumorzelle vernichten. In diesem Artikel 
kombinieren wir anti-MARCO Antikörper mit anderen Immuntherapie-Antikörpern, die auf 
die Moleküle PD-1 und PD-L1 gerichtet sind und sehen erneut, dass eine Kombination 
hervorragende Ergebnisse zeigt und wir noch kleinere Tumore bekommen als in den 
Einzelbehandlungen. Ein weiterer wichtiger Bestandteil dieser Studie ist, dass wir Antikörper 
spezifisch für den menschlichen MARCO Rezeptor statt dem Maus Rezeptor hergestellt haben. 
Somit können wir nun auch menschliche Zellen erreichen und sehen in in vitro Experimenten 
in der Petrischale, dass die Behandlung von menschlichen MARCO+ Makrophagen mit dem 
Antikörper ebenfalls zur Umprogrammierung der Makrophagen zu einem anti-tumoralen 
Status führt, so wie in den Mäusen. Für diese Experimente in der Petrischale werden die Zellen 
in sogenannten tumor-konditioniertem Medium kultiviert. Dies ist das Medium, in dem vorher 
echte Krebszellen gehalten wurden und somit alle Stoffe enthält, die sonst auch im wirklichen 
Tumor im Körper von den Krebszellen ausgeschüttet werden. Dieses System dient dazu, die 
Tumorkonditionen bestmöglich und so realitätsgetreu wie möglich zu simulieren. In den 
Petrischalen-Experimenten sehen wir, dass die einzelnen Immunzellen unterdrückt und 
ausgeschaltet werden. Wenn wir die Makrophagen vorher aber mit unseren anti-humanen 
MARCO Antikörpern behandeln, können wir wichtige Immunzellen retten und wieder ihre 
anti-tumor Aktivität und Tötungskapazität erhöhen. Eine dieser Immunzellen sind die bereits 
oben genannten NK Zellen. 
In Artikel IV beschäftigen wir uns mehr mit MARCO im Menschen und fokussieren uns hier 
auf Pankreaskrebs, einer der schlimmsten, schwer heilbaren Krebsarten. Auch dort finden wir 
MARCO auf pro-tumoralen Makrophagen im Tumor und können in der Petrischale zeigen, 
dass auch im Bezug auf Pankreaskrebs, die Behandlung der Makrophagen mit den anti-
MARCO Antikörpern zu erhöhtem Töten von Tumorzellen und vermehrter Aktivität von T 
Zellen und NK Zellen führt. 
Zusammenfassend kann man sagen, dass diese Arbeit Einsicht in die Biologie von dem 
Rezeptor MARCO gibt und wir nun wissen, dass er als immuntherapeutisches Ziel geeignet 
ist. Mithilfe von auf MARCO gerichteten Antikörpern können wir den Tumor modulieren und 
die dort vorhandenen Immunzellen re-programmieren, die vorher vom Tumor unterdrückt 
wurden. So erzielen wir eine Reduktion des Tumors und re-aktivieren die Abwehrzellen , die 
ihrer Aufgabe wieder nachgehen und den Krebs bekämpfen. Unsere Ergebnisse sind 
vielversprechend und helfen dabei, klinische Studien zu planen und anti-MARCO Antikörper 
herzustellen, die dann eventuell in Kombination mit anderen Therapiemöglichkeiten an 
Krebspatienten angewendet werden können.  
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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
The immune system is the host`s line of defense against infectious agents and an important 
player in maintaining tissue homeostasis. Its development starts during embryogenesis and 
until birth it has evolved as a sophisticated network of effector cells and molecules that still 
develops during life and discriminates between self and non-self.   
Some of the first experiments in the field of immunology go back to Edward Jenner who 
protected a young man against smallpox by administration of cowpox virus in 1796. This was 
the first proof of immunological memory and the first step into the field of vaccinations. 
Another pioneering finding was discovered by Ilya Metchnikoff in 1866 when he discovered 
leukocytes were able to migrate to the site of infection, engulfing and digesting pathogens. He 
named the cells “phagocytes” and the process phagocytosis 1 which we today know as a part 
of the unspecific and quickly responding innate immunity. Metchnikoff was awarded the Nobel 
Prize for Physiology or Medicine in 1908 as his discovery was the birth of cellular immunity. 
In the late 19th century, more groundbreaking discoveries were made: In 1884, Robert Koch 
identified that specific microorganisms are responsible for certain infectious diseases, 
including tuberculosis. Furthermore, Louis Pasteur was inspired by Edward Jenner and 
discovered a vaccine against chicken cholera in the 1880s realizing that old bacteria are not as 
deadly and can be used for immunization. Paul Ehrlich was one of the first to postulate that 
antitoxins, today known as antibodies (Abs), are produced to battle bacteria and bind bacterial 
toxins. In the 1890s, Emil von Behring and Shibasaburo Kitasato discovered that the serum of 
animals contained soluble factors that neutralize toxins released by bacteria. Besides studies 
dealing with soluble Abs and cellular immunity, Jules Bordet discovered the complement 
system in 1899 as she detected that heat-stable antitoxins as well as heat-sensitive components 
in the serum were responsible for the disruption of bacterial cell membranes and they act 
together with Abs to kill pathogens. 
As we know today, the immune system consists of two branches, the innate and the adaptive 
immune system – a sophisticated network of highly specialized immune cells which collaborate 
to protect the host from infection and maintaining tissue homeostasis. Here, the two branches 
will be discussed and the cells and mechanisms most important for this thesis are emphasized.  
1.1.1 Lymphoid organs 
The development of most immune cells starts in the bone marrow where leukocytes emerge 
from hematopoietic stem cells (HSC) in the process of “hematopoiesis” before they 
differentiate further into lymphoid or myeloid lineage cells. Besides that, cells of the myeloid 
lineage can also originate in the yolk sac or fetal liver during embryogenesis. There are central 
or primary lymphoid organs where lymphocytes are produced and peripheral or secondary 
lymphoid organs where naïve lymphocytes are maintained and antigens are presented to them, 
thus adaptive immune responses are initiated.  
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The central or primary lymphoid organs are the bone marrow (where B cells develop) and 
thymus (the site where T cells arise from); the peripheral or secondary lymphoid organs include 
spleen and lymph nodes. Sometimes people also refer to tertiary lymphoid tissues which 
include Peyer`s patches, mucosa/gut- associated lymphoid tissues (MALT/GALT) and tonsils. 
These are the tissues where immune cells perform immunoregulatory functions. To move 
through the body and to distant sites, immune cells travel through blood vessels and specialized 
vessels called lymphatics. 
The spleen is the biggest peripheral lymphoid organ and together with lymph nodes these are 
the sites where immune cells have cell-to-cell contact to start immune responses and there are 
B cells, T cells and monocytes present. The spleen is divided into red pulp and white pulp: In 
the red pulp there are mainly red pulp macrophages screening for pathogens and removing 
damaged and aged red blood cells. The white pulp is the site where innate meet adaptive 
immune cells to initiate immune responses. It consists of strictly determined structures 
including T cell and B cell follicles. In the latter, the antigen (Ag) specific adaptive immune 
response arises, and germinal centers (GC) are formed. In rodents, the lymphoid white pulp 
and the scavenging red pulp is separated by the marginal zone (MZ) (Figure 1). The MZ is 
critical for capturing blood-borne pathogens by highly specialized phagocytes, such as 
marginal zone macrophages (MZMs), metallophilic macrophages (MMs) and dendritic cells 
(DCs). These phagocytes express a variety of pattern recognition receptors (PRR) to detect a 
wide spectrum of microbial antigens. MZMs are crucial players in this process 2 and align the 
outside of the MZ. Next to the highly phagocytic MZMs, MMs are located on the inside of the 
MZ 3. Besides macrophages, there is a distinct B cell type present in the MZ, called the marginal 
zone B cells (MZBs). MZBs are located strategically well and can respond quickly initiating T 
cell independent immune responses. Inside the follicular (FO) area of spleen and also lymph 
nodes there is a B cell subset that it different than the MZB called FO B cells (FOBs). FOBs 
represent the majority of B cells in the spleen 4,5 and 
are the ones that are involved in T- cell – dependent 
Ab responses. MZBs are known to travel between 
the MZ and follicle transporting captured Ag into 
the follicles and deposit Ag on follicular dendritic 
cells (FDCs) 6–9. Furthermore, it has been shown 
that the interaction between MZMs and MZBs is 
required to retain the MZ structure 10. In chapter 
1.2.2 the interdependence of MZMs and MZBs are 
described in more details and paper I in this thesis 
thematizes how the crosstalk between MZMs and 
MZBs can be modulated. 
  
Figure 1:  Structure of the marginal zone in the 
spleen. MARCO on marginal zone macrophages 
(red), F4/80 on red pulp macrophages (white). 
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1.1.2 Innate immune system  
The innate immune system is the first line of defense against infectious agents and invading 
microorganisms which is already functional at birth and has been found in invertebrates and 
vertebrates. The innate immune system consists of physical barriers such as skin and mucosa, 
but also of anti-microbial plasma proteins (complement) and innate immune cells. The latter 
are mostly myeloid cells, including monocytes, macrophages, DCs and granulocytes 
(neutrophils, basophils, eosinophils, mast cells) but also include natural killer (NK) cells and 
innate lymphoid cells (ILC) that have lymphoid progenitor cells. The innate immune response 
is also called “unspecific immunity” as it acts rapidly and distinguishes between “self” and 
“non-self” based on widely conserved domains that are expressed on pathogens but 
differentiate host cells. These structures are called danger-associated molecular patterns 
(DAMPs) and pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide 
(LPS) or double stranded RNA 11 and are recognized by a variety of PRRs. PRRs can be on the 
cell surface such as scavenger receptors, Toll-like receptors (TLR), c-type lectin receptors and 
complement receptors or intracellularly, such as retinoic acid- inducible gene (RIG)-I-like 
receptors (RLR), NOD-like receptors. Ligand binding by PRRs can result in the internalization 
of the receptor for further degradation mediating a tailored immune response 12,13. Extracellular 
adenosine triphosphate (ATP) is also known as a danger- signal that can activate immune cells, 
polarizes macrophages towards an inflammatory state and leads to inflammation 14,15. 
Extracellular ATP can be sensed by ATP-sensing receptors, such as P2X purinoceptor 7 
(P2X7R) which leads to intracellular signaling and activation of the immune cells 16,17 or it is 
broken down to adenosine monophosphate (AMP) by ectonucleotidase CD39 and further 
processed to adenosine by CD73 which is known for its immunomodulatory effects 18. 
Adenosine can suppress T cell proliferation, the release of pro-inflammatory cytokines and 
cytotoxic activity by NK cells 19,20. Upon the detection of pathogens, innate immune cells take 
action against them and some travel to peripheral or secondary lymphoid organs initiating 
adaptive immunity resulting in the eradication of the intruder.  
1.1.3 Adaptive immune system 
In contrast, the second branch of the immune system is the adaptive immune system that 
includes humoral and cell-mediated immunity. It ensures Ag-specific immune responses as 
well as memory and is acquired during life. Adaptive immune responses have been only found 
in vertebrates. B and T lymphocytes are the players of the adaptive immune system and in 
contrast to innate immune responses, they need to encounter the Ag they are specific for to be 
activated and able to combat it. Thus, the initiation of an adaptive immune responses takes 
more time compared to innate immunity but also has a memory which innate immune cells do 
not provide. While B cells complete their development in the bone marrow, T cell precursors 
migrate to the thymus for their maturation. Adaptive immune responses provide immunity 
against most pathogens faced during a lifetime. In adults, most of the B cells still arise from 
bone marrow precursors whereas T cell production in the thymus is decreasing and T cell 
numbers are maintained by the division in the periphery. Upon Ag recognition, B and T cells 
undergo rapid clonal expansion and selection processes to avoid auto-reactive cells. It depends 
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on the Ag which kind of T cells will be activated: different subtypes of T helper (TH) cells to 
suppress or modulate the immune response or cytotoxic T cells for the killing of infected and 
aberrant cells. Upon activation, B cells undergo affinity maturation and are responsible to 
produce Ag-specific Abs. 
1.2 LYMPHOID CELLS 
Arising from HSC during hematopoiesis in the bone marrow, lymphoid progenitors give rise 
to B cells, T cells, NK cells and innate ILCs but also γδ T cells and NKT cells. As important 
cell types for this thesis, only T cells, B cells and NK cells will be further described here.  
1.2.1 T cells 
T cells arise from the common lymphoid progenitor (CLP) and belong to the adaptive immune 
system. Precursor cells migrate to the thymus to become mature T cells which express a unique 
T cell receptor (TCR) that recognizes peptides in complex with major histocompatibility 
complex (MHC) on the surface of antigen presenting cells (APCs). The TCR consists of two 
glycoprotein chains, most of the T cells will become αβ T cells, whereas only around 5% will 
become γδ T cells. Besides TCRs, T cells express one of the co-receptors CD4 or CD8 which 
mostly determines which kind of antigens the cell will recognize: Ags presented in MHC-I 
complexes activate CD8+ T cells (endogenous agents), MHC-II Ag complexes will activate 
CD4+ T cells (exogenous agents). γδ T cells can mostly be found in epithelial and mucosal sites 
where they reside and do not express CD4 or CD8. However, it remains unknown which 
ligands γδ T cells have but they are thought to be not restricted to MHC molecules. Before T 
cells are released to the circulation, they undergo several maturation steps to ensure recognition 
of peptides in complex with self- MHC molecules (positive selection) but also to avoid self-
reactive T cells that interact strongly with self-molecules by depletion as they undergo 
apoptosis (negative selection). The remaining cells are mature naïve T cells which enter the 
circulation and secondary lymphoid organs to encounter their specific Ag presented by APCs. 
Activation of CD4+ and CD8+ T cells always requires APCs that present the Ag in form of a 
peptide-MHC complex to T cells. DCs are the most professional and potent APCs but also 
other cells, such as B cells or macrophages can present Ag to T cells. 
After activation, T cells undergo clonal expansion and differentiate into effector T cells 
dependent on the nature of the Ag. These effector T cells either migrate to the site of infection 
to kill infected or malignant cells or activate macrophages. CD8+ T cells are appreciated as 
cytotoxic T cells that remove target cells. However, T cells can also travel to B cell areas to 
provide help to B cells for a proper humoral immune response (follicular Th cells). CD4
+ T 
cells are considered as Th cells and can further be divided into Th1, Th2, Th9, Th17, Th22 and T 
regulatory (Treg) subsets each with a unique repertoire of cytokine production 
21,22. Th1 and 
Th17 cells are known to support inflammation by the production of interferon gamma (IFN-γ) 
and thus activate cytotoxic cells, such as macrophages, NK cells and cytotoxic CD8+ T cells. 
Furthermore, Th17 cells produce cytokines, such as IL-17 and IL-21 and thus, support an 
inflammatory response. IL-17 can induce pro-inflammatory cytokine production and 
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recruitment of neutrophils, IL-21 stimulates the proliferation of CD8+ T cells and induces NK 
cells activity and increases their cytotoxicity 21,23. Th2 cells help B cells to implement a humoral 
immune response and to differentiate into Ab producing plasma cells by secreting IL-4 and IL-
10 amongst other cytokines. Treg cells are a more immune suppressive T cell subset, defined by 
the expression of CD25 and transcription factor FoxP3 and they are known to express IL-10 
and TGF-β 24. Th22 cells express IL-22 and are mainly suggested to be involved in the 
pathogenesis of skin inflammatory diseases 22. The most recently defined Th cell subset are Th9 
cells which have been so far classified as Th2 cells but recently got classified as IL-9 producing 
Th9 cell. They arise upon IL-4 and TGF-β stimulation and their main cytokine producing is IL-
9, but they have also been shown to secrete IL-10 and IL-21 21,25. IL-9 has many effects on 
several immune cells, such as supporting immune suppressive functions of Tregs or promoting 
Th17 proliferation and it has been demonstrated to be inflammatory (promotes allergic airway 
inflammation) as well as anti-inflammatory (experimental autoimmune encephalomyelitis) so 
there is still a need of uncovering the nature of IL-9 and its effect on the immune system 26.  
Cytotoxic CD8+ T cells can also be activated through the interaction with other immune cells. 
Activated NK cells produce IFN-γ which mediates DCs to secrete IL-12 that further enhances 
CD8+ T cells response and tumor killing 27. Moreover, the re-polarization of TAMs towards a 
pro-inflammatory phenotype using cryo-thermal therapy in B16 melanoma resulted in the 
generation of cytotoxic CD8+ T cells, supporting anti-tumor CD4+ T cell activation and anti-
tumor response 28. Thus, the interaction with other immune cells is needed for potent T cell 
activation.  
1.2.2 B cells 
B cells belong to the adaptive immune system and are a distinct and unique cell type as they 
are the only Ab-producing cells of the immune system. Other functions are Ag presentation, 
cytokine production and they are involved in the generation of immunological memory. In 
1890, the existence of antitoxins in the serum of animals has been discovered to provide 
immunity against diphteria and tetanus 29. However, the discovery of the cells producing these 
antitoxins was only in 1965/66 by Max Cooper and Robert Good when they used chickens as 
model system and found that cells from the bursa of Fabricus (equivalent to the bone marrow) 
are responsible for antibody production (B cells) 30,31.  
B cells develop from CLPs in the bone marrow where they go through several developmental 
stages: from CLP to early pro-B cells, late pro-B cells, pre-B cell to immature B cells. During 
that time B cells encounter as many Ags as possible to develop their unique B cell receptor 
(BCR) that is highly Ag specific. The BCR is a surface-bound immunoglobulin (Ig) and 
consists of a heavy and a light chain that binds to the Ag through its complementarity 
determining regions (CDRs). To provide a big repertoire of different BCRs, B cells undergo 
random gene rearrangement of their immunoglobulin (Ig) gene segments. A lot of B cells will 
be auto-reactive and will undergo receptor editing or clonal deletion – these are the mechanisms 
to protect the host against auto-reactive immune cells and is called “central tolerance”. All this 
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results in a plethora of many different BCRs (up to 108 distinct receptors in the repertoire are 
possible) and thus, providing the selectivity and specificity of the adaptive immune system.  
Non self-reactive B cells leave the bone marrow as immature transitional 1 (T1) B cells, migrate 
to splenic B cell follicles where they mature to T2 B cells. T1 B cells are characterized by their 
IgM expression, once they mature they become T2 B cells and gain IgD surface expression 32. 
Furthermore, T1 B cells do not express CD21 (complement receptor 2) yet, whereas T2 B cells 
do express CD21 24.  
Mature B cells can then be divided into B-1 and B-2 cells 33,34. In rodents, B-1 cells can mainly 
be found in the pleural and peritoneal cavities and are also referred to as innate-like B cells. 
CD5+ B-1 cells develop already from fetal liver hematopoiesis and are long-lived self-renewing 
cells 33. Murine B-1 cells have been shown to be the main producers of natural Ab pool. These 
are spontaneously secreted IgM Ab that are also expressed in steady-state conditions to act on 
pathogens quickly 35. In contrast, B-2 cells become follicular (FO) or MZ B cells. FOBs are the 
most occurring B cell type in secondary lymphoid organs and they are homing to B cell follicles 
close to the T cell areas 33. Upon T cell help, naïve FOBs undergo proliferation and can 
differentiate into plasma cells or memory B cells. In contrast, MZBs are self-renewing and non-
circulating B cells resident in the splenic MZ. They are strategically well located to capture 
blood – borne pathogens in proximity to the APCs MZMs and DCs. MZBs are known to initiate 
rapid T-independent (TI) responses and are characterized by the expression of CD21 and 
CD1d. CD21 plays a crucial role in shuttling antigens to the follicle and CD1d is required to 
interact with natural killer T (NKT) cells by presenting lipid Ags 4,33,34. MZBs are known to 
receive Ag from MZMs 4,36 and MZBs transport Ag into the follicle for deposition on FDCs 
6,37. MZBs regulate the capture capacity of MZMs as the depletion of MZBs results in less Ag 
capture by MZMs and less SIGN-RI+ MZMs which in turn also affects the Ag capturing by B 
cells 38. The interaction between MZBs and MZMs is important for the trafficking of MZBs to 
the follicle 10. The interdependence of MZMs and MZBs is also validated by the fact that the 
loss of B cells led to the loss of MZMs and vice versa the loss of MZMs affected MZBs 
numbers 10,39; furthermore, MZMs have been shown to be responsible for the retention of MZB 
10. 
The activation of B cells depends on the nature of the Ag: Upon encountering their specific 
Ag, B cells get activated and differentiate into Ab producing plasma- or memory B cells that 
are ultimately required for the humoral immunity. Non-protein Ags, such as lipids, do not need 
T cell involvement for activation and Ab production by B cells and are referred to as thymus-
independent (TI) Ags. In contrast, there are protein Ags that do require the interaction of T and 
B cells; thus, these are called thymus-dependent (TD) antigens. TI immune responses can be 
further divided into type I and type II Ags. Type I Ags stimulate B cells through TLRs, whereas 
type II Ags are usually large polysaccharides with multiple antigenic binding sites crosslinking 
BCRs and thus activating B cells. TI Ags usually result in low affinity, mostly IgM Ab 
production and the response is short-lived compared to TD responses. In contrast, TD B cell 
activation requires potent T cell help. In lymphoid organs, naïve CD4+ T cells recognize Ags 
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presented by APCs in the T cell area. At the same time, B cells encounter the same pathogen 
with their BCR which gets them activated and induces them to move towards the interface 
between B and T cells zone in lymphoid organs. B cells that get activated through BCR 
engagement also upregulate co-stimulatory molecules, internalize the Ag, processing and 
presenting it in the MHC-II molecule. The CD4+ T cells in turn recognize the antigen-MHC-II 
complexes and further binding through co-stimulatory molecules activates the T cells to 
proliferate. These T cells are also called T follicular helper cells (TFH cells) and upon activation 
they upregulate CD40 ligand (CD40L) which binds CD40 on B cells and produce cytokines 
that promote B cell proliferation and differentiation into Ab-producing cells. At this stage, TFH 
cells determine the required Ab isotype by supporting isotype switching through cytokine 
production (for instance, IL-4 for IgG1 Ab, IFN-γ for IgG2a, TGF- for IgG2b). The Ab 
isotype determines the Fc receptor specificity on effector cells leading to different function of 
immune cells. The proliferation of B cells in response to a TD Ag is called germinal center 
formation (GC) and occurs in the interface between B and T cell follicles in secondary 
lymphoid organs. Besides proliferating B cells, FDCs can be found in the GC that support B 
cell proliferation in the dark zone of the GCs before B cells migrate to the light zone where 
they undergo affinity maturation, needing help from FDCs and TFH cells. Here, long-lived 
plasma cells and memory cells are created. Through somatic hypermutation, mediated by the 
gene activation-induced deaminase (AID) which is also responsible for isotype class switching 
40, B cells are going through the process of affinity maturation and only the B cells with Ab of 
the highest Ag affinity are selected and survive. These activated B cells then differentiate into 
plasma- or memory cells that can be found in extrafollicular areas in lymphoid organs or they 
migrate back to the bone marrow where they reside. 
Besides their primary role in humoral immune responses, B cells also have other functions, 
such as antigen presentation 41, the production of immunomodulatory cytokines, including IL-
2, IL-4, IL-6, IFN-γ, IL-12 or TNF- α and the regulatory B cell (Breg) subtype that is known to 
produce the immune suppressive molecules IL-10 and TGF- β 42 .  
Auto-reactive B cells play a crucial role in many autoimmune diseases, such as Systemic lupus 
erythematosus (SLE) where B cells have been identified as the main players 43. SLE can affect 
every organ and autoantibodies are the hallmark of this disease, such as anti-DNA or anti-
MARCO autoantibodies 43,44. 
1.2.3 Innate lymphoid cells and natural killer cells 
Natural killer (NK) cells were discovered in 1975  simultaneously by Rolf Kiessling, Eva Klein 
and Hans Wigzell at Karolinska Institutet in Stockholm 45,46 and Herberman et al. at the 
University in Pittsburgh 47,48. They were described as a subset of lymphocytes that can 
spontaneously kill tumor cells without any pre-stimulation and in 1986 Klas Kärre 
demonstrated their killing mechanism by proposing the ”missing-self” theory 49,50. In mice, NK 
cells are characterized as NK1.1+ NKp46+ CD3- cells; in humans, NK cells are mostly divided 
into two subsets CD56dim CD16+ and CD56bright CD16dim/-. The CD56dim CD16+ population 
constitutes 90% of all NK cells, is mostly present in the circulation and shows enhanced 
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cytolytic and killing capacity compared to CD56bright CD16dim/- NK cells which are the cytokine 
producing subtype 51. NK cells were always counted as the third largest lymphocyte population 
besides B and T cells. However, recently they got re-categorized and classified as a member of 
the innate lymphoid cells (ILCs). The group of ILCs counts five members: NK cells, ILC1, 
ILC2, ILC3 and the lymphoid tissue inducer cells 52. 
NK cells express a mixture of activating and inhibitory receptors that are important for their 
cytolytic function. As the “missing-self” theory states, NK cells recognize self-MHC 
complexes on the surface of cells which leads to their inhibition through the inhibitory killer 
cell Ig-like receptors (KIRs) in humans and the Ly49 receptor family in mice. During their 
development, NK cells have been educated to recognize a plethora of self MHC-I – antigen 
complexes. However, when the cognate self-MHC-I molecules are missing because pathogens 
or tumor cells abrogate its expression as an immune escape route, NK cells get activated and 
kill this cell 49,50. But NK cells can also kill by ligation of their activating receptors, such as 
DNAM1, NKp44, NKp46, NKG2D whose ligands are expressed on malignant or infected 
cells. Therefore, the activation state of NK cells is highly dependent on the balance of inhibitory 
and activating signals.  
NK cells store cytotoxic granules in their cytoplasm containing effector molecules, such as the 
pore-forming molecule perforin or protease granzyme B which are released upon activation. 
Together they lead to pore formation in the membrane of target cells and subsequently to their 
death. NK cell killing mechanisms also comprise receptors that are mediating target cell killing, 
such as Fas ligand or tumor necrosis factor- related apoptosis-inducing ligand (TRAIL). Its 
ligands death receptors 4 (DR4) and DR5 belong to the TNF superfamily “death” receptors and 
are expressed on many cells including tumor cells. Upon binding, TRAIL stimulates DR4/DR5 
expressing cells to undergo apoptosis in a caspase – 8 dependent matter. Another receptor – 
dependent way of killing is mediated by Fc receptor CD16 (FcγRIII in mice, FcγRIIIa/b in 
humans) which is expressed by NK cells. CD16 binds the Fc part of Abs and this cross-linking 
leads to antibody dependent cell cytotoxicity (ADCC) of target cells. 
ILCs have been identified to initially arise from the fetal liver 53,54 but in adults they develop in 
the bone marrow from the same progenitor as B and T cells that is called CLP. The transcription 
factor Id2 (inhibitor of DNA binding2) is the main transcription factor responsible for the fate 
of cells to become an ILCs and no B or T cell. ILCs leave the bone marrow to populate 
lymphoid as well as peripheral organs (mucosal tissues), such as the dermis, liver, small 
intestine and lung, where they reside in the tissues and maintain homeostasis 24,52. ILCs share 
transcription factors with T cells and produce similar cytokines. Therefore, ILCs have been 
divided into cytotoxic cells (NK cells), ILC1, ILC2 and ILC3 – mirroring the functions of T 
cell subsets: type 1, type 2 or type 17 T subpopulations 55.  
ILC1s and NK cells are the closest related subsets within the ILC group and both cell type 
respond to IL-12 and IL-18 with the production of IFN-γ. However, they can be distinguished 
by their transcription factors which is the best way of discriminating these cell types: They are 
both RORγt- T-Bet+ GATA3int but only NK cells are also Eomes+ 55. Other differences between 
  9 
ILC1s and NK cells are that NK cells can be found in the circulation, while ILC1s seem to 
mainly be tissue-resident cells and NK cells are more similar to cytotoxic CD8+ T cells whereas 
ILC1s seem to be more like Th1 CD4
+ T cells. 
1.3 MYELOID CELLS 
 
Myeloid progenitors can develop in the bone marrow and give rise to granulocytes (basophils, 
eosinophils and neutrophils) and monocytes which can subsequently differentiate into 
macrophages or DCs. As the important myeloid cells for this thesis are the macrophages, 
only they will be described here in detail besides myeloid-derived suppressor cells (MDSCs). 
1.3.1 Monocytes 
 
Blood monocytes can be distinguished into two subsets based on their receptor expression and 
migratory capacities: In mice, there are CX3CR1intLy6C+ (in humans CD14+CD16-) and 
CX3CR1highLy6C- cells (in humans CD14+/mid CD16+). CCR2+CX3CR1intLy6C+ is the subset 
that is migrating towards the site of an inflammation whereas the CCR2lowCX3CR1highLy6C- 
subset is the “patrolling” monocyte 56,57. In the absence of an inflammation, CX3CR1intLy6C+ 
monocytes can travel back to the bone marrow and convert to CX3CR1highLy6C- 58. Leaving 
the bone marrow and the recruitment to sites of inflammation is dependent on CCR2-CCL2 
signaling 59.  
1.3.2 Macrophages 
 
Macrophages are professional phagocytes that belong to the innate immune system and are 
crucial for the clearance of pathogens but also involved in the maintenance of tissue 
homeostasis. Phagocytes were discovered by Ilya Metchnikoff in 1866 when he found that 
leukocytes were able to migrate to the site of infection and ingest pathogens. For this, he used 
starfish larvae and pricked them with thorns to activate their immune cells to attack the 
foreign invader. He named this process phagocytosis and the cells phagocytes from Greek 
phago = to devour and cytos = cells 1. 
Macrophages are tissue-resident cells that are needed for clearing pathogens, removing old or 
damaged erythrocytes in the spleen and liver but also to phagocyte cells debris and apoptotic 
cells 60. Besides that, they fulfill a plethora of other functions as the regulation of tissue 
homeostasis, tissue remodeling and initiating adaptive immune responses through cytokine and 
chemokine production 61. The main regulator of macrophages is colony-stimulating factor 1 
receptor (CSF1R) which ligand is CSF1. Macrophages rely on macrophage-colony stimulating 
factor (M-CSF) for their survival. Their name originates from Greek and means “large eaters”, 
makros = large and phagein = eat. 
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1.3.2.1 Ontogeny of macrophages 
For decades, it was believed that all macrophages origin from blood-circulating monocytes that 
derive from a BM progenitor and that these monocytes constantly replenish the pool of tissue-
resident macrophages. This founded on the concept of the “mononuclear phagocyte system” 
proposed by van Furth in the 1970s 62. However, the “mononuclear phagocyte system” has 
been refuted and fate-mapping studies revealed that most of the tissue-resident macrophages 
develop already during embryogenesis in the yolk sac or fetal liver and renew themselves 
during adulthood, such as microglia (brain), Kupffer cells (liver), alveolar (lung) and splenic 
red pulp (spleen) macrophages 63. However, under inflammatory conditions circulating 
monocytes can still give rise to tissue-resident macrophages 64–66. Moreover, a pool of 
monocytes resides in the spleen which can replenish tissue-resident macrophages and deals as 
reservoir of inflammatory monocytes that can be rapidly recruited in case of an inflammation 
67. In contrast, dermal macrophages and the ones found in the intestine are constantly replaced 
by blood circulating monocytes 68. Taken together, most macrophage populations are 
maintaining themselves by local proliferation throughout the lifetime 68.  
1.3.2.2 Macrophage subsets 
Macrophages exist nearly in all tissues and can be found in lymphoid organs as well as in non-
lymphoid tissues. They are very plastic cells which are affected by tissue-derived factors as 
part of their local education. Alveolar macrophages with fetal origin usually have a non-
inflammatory state and equipped with many PRRs they are responsible for the removal of air-
borne pathogens and apoptotic cells. Kupffer cells, the liver-resident macrophages, filter the 
blood not only for pathogens but also remove potentially harmful agents such as malformed 
erythrocytes, extracellular matrix components and regulate plasma cholesterol. Osteoclasts, the 
macrophages in the bones, are required for bone resorption and bone formation during 
embryogenesis. However, it is still disputed whether they origin pre- or postnatally. Microglia 
are the tissue-resident macrophages of the central nervous system and the first macrophages 
shown to be independent from bone marrow-derived monocytes. They exclusively derive from 
the embryonic yolk sac and replenish themselves during life. Macrophages are also present in 
the peritoneal cavity that rely on the transcription factor Gata-6 in contrast to other tissue-
resident macrophages. Gata-6 is induced by retinoic acid that can be found in high amounts in 
the omentum and thus contributing to the tissue-specific education of these peritoneal 
macrophages 69. As they are easy to access, peritoneal macrophages have been the subject of 
many studies about signaling, cytokine and chemokine production after pathogen stimulation 
and processes of phagocytosis. It is still largely unknown whether these cells origin from 
embryogenic progenitors or HSC in the bone marrow – however, there are two peritoneal 
macrophage populations F4/80high CD11bhigh (also referred to as large macrophages) and 
F4/80int CD11bint (also referred to as small macrophages) which might explain the origin. It has 
also been proposed that F4/80int CD11bint macrophages are a precursor for the mature F4/80high 
CD11bhigh macrophages 70 63 59. Macrophages in the gut are sentinels and besides the removal 
of pathogens they maintain tolerance to the gut flora and food. 
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The spleen is the largest lymphoid organ and the main site where adaptive immunity to blood-
born invaders is initiated. The spleen acts as a filter, is highly structured and homes several 
macrophage subsets with specific functions: Red pulp macrophages are the most prominent 
macrophages in the spleen, specialized in uptake of senescent or damaged red blood cells and 
recycling of heme and iron 71,72. The red pulp is also the place where monocytes are stored that 
can react rapidly in case of inflammation and migrate to the site of inflammation 67. The splenic 
white pulp contains macrophages within the GC regions called tingible- body macrophages 
removing apoptotic B cells during GC reactions 59. The boundary between red and white pulp 
is the MZ and contains two highly specialized macrophage subtypes: marginal zone 
macrophages (MZMs) and metallophilic macrophages (MMs). When blood enters the spleen, 
the blood flow slows down and macrophages screen for potential threats and remove apoptotic 
cells. Moreover, MZMs are responsible to inhibit immune responses against apoptotic cells 73. 
MMs align the inner layer of the MZ whereas MZMs are located on the outer site of the MZ. 
Both macrophage subsets are dependent on the transcription of nuclear liver-X receptor α 74. 
MMs are characterized by the expression of CD169 (Siglec-1, sialoadhesin) which allows them 
to take up sialic acid-expressing bacteria 75.   
MZMs are of particular interest for this thesis as they express the class A scavenger receptor 
MARCO (macrophage receptor with collagenous structure) 44,76–78 that is described in more 
detail later. MZMs are scaffolded with many PRRs for the uptake and clearance of blood-borne 
pathogens. Besides MARCO they express C-type lectin CD209b (SIGN-RI). Upon the 
activation of MZMs with LPS the receptors behave differently: Whereas SIGN-RI is 
downregulated, MARCO engagement leads to the release of pro-inflammatory cytokines 79–81. 
The expression of MARCO on MZMs is important for the retention of MZBs 10 and moreover, 
the colocalization of MZMs and MZBs is required for early IgM production by MZBs in 
response to bacteria. This strongly suggests that MZMs can present Ags to MZBs to support 
early responses against polysaccharides 82. In turn, MZBs release chemokines, such as CCL19 
and CCL21, that are needed for the retention of MZMs 83 and regulate their SIGN-RI 
expression 38. Binding of intravenous Ig (IVIG) to SIGN-RI on MZMs leads to the mediation 
of anti-inflammatory responses due to the engagement of inhibitory FcγRIIb. IVIG is 
commonly used for treating chronic autoimmune diseases because it inhibits autoantibody-
mediated inflammation by increasing the activation threshold 84,85.  
Lymph nodes show a similar structure compared to the spleen and filter the lymph for lymph-
borne pathogens. There are three distinct macrophage subsets present in the lymph nodes: 
medullary sinus macrophages (MSMs), medullary cord macrophages (MCMs) and subcapsular 
sinus macrophages (SSMs) 86. Medullary macrophages also express MARCO to efficiently 
clear pathogens and foreign particles from the lymph 78. In steady state, the medulla represents 
a small part of the lymph node but can become enlarged upon plasma cell response 86. The 
SSMs are CD169+ such as MMs in the spleen. SSMs can ingest viruses from the lymph 
circulation and initiate antiviral humoral immune responses by transferring the Ag to B cells 
87. MSMs also express CD169 86.  
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1.3.2.3 Macrophage polarization 
Macrophages are very plastic cells that can change phenotypically but also on transcriptional 
level dependent on their microenvironment and the surrounding stimuli. The first time the term 
“macrophage activation” was introduced was in 1962 by Mackaness. He recorded enhanced 
microbicidal capacity of macrophages against several microorganisms 88 which two decades 
later traced back to be dependent on IFN-γ and that the activation of macrophages also changes 
their metabolism 89. In 1992, Stein et al. discovered the alternative activation of macrophages 
that was independent on IFN-γ but dependent on IL-4 stimulation leading to different 
phenotypic changes than the classical activation including the expression of mannose receptor 
(CD206) 90. These were the beginnings of the attempt to classify the complex and diverse 
macrophage populations. Mills et al. were the first to define the M1/M2 axis for macrophage 
polarization according to their function and to mimic the Th1 and Th2 T cell subsets. He defined 
“M1 to be able to kill whereas M2 macrophages are able to heal” 91. Thus, macrophages have 
been distinguished into two extreme states and the M1 term was further used for classically 
activated macrophages 89 and M2 as alternatively activated macrophage 92,93. Later based on 
the great plasticity of macrophages, Mosser and Edwards proposed a classification with 
continuous transitions instead of two extremes (M1 and M2) in form of a colored wheel and 
suggested three main macrophage functions: immune regulation, wound healing and host 
defense, but with transition states in between these main subtypes 94.  
The classical activated M1 macrophages are pro-inflammatory and involved in host defense. 
They arise upon stimulation with IFN-γ and/or TLR ligands, such as LPS. IFN- γ signals 
through STAT1 and interferon regulatory factors (IRF), such as IRF-1 and IRF-8, inducing 
cytokine receptors, such as IL-15R , IL-2R and IL-6R 93. IFN-γ can be produced by many cell 
types and one important source are activated NK cells which then support the shift to M1 
macrophages, expression of pro-inflammatory cytokines and enhance their killing capacity 
95,96. LPS activates MyD88-dependent signaling pathways resulting in the expression of pro-
inflammatory cytokines, such as IL-12, IL-6, IL-1β , TNF, IL-23; chemokines, such as 
CXCL10 , CXCL11 and CCL2; co-stimulatory molecules, such as CD86; and MHC-II 
molecules for increased Ag presentation  93,94. IL-23 has been shown to be crucial for the 
expansion of Th17 cells which in turn secrete TNF-α and IL-6 supporting an inflammatory 
milieu 97. Recently, granulocyte-macrophage colony-stimulating factor (GM-CSF) has also 
been defined as stimulator for M1 macrophages 98. Furthermore, M1 macrophages have 
increased expression of Nos2 which is encoding for the enzyme inducible nitric oxide synthase 
(iNOS). iNOS metabolizes L-arginine and synthesizes nitric oxide (NO) 99. Thus, increased 
NO production results in augmented production of reactive oxygen species (ROS) and 
therefore to enhanced cytotoxic function against pathogens 100. Therefore, pro-inflammatory 
M1 macrophages are important players in host defense and competent in clearing pathogens. 
However, M1 macrophages responses can also damage host tissues and they are known key 
players in many autoimmune diseases, such as rheumatoid arthritis 101,102. 
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In contrast, alternatively activated M2 macrophages can be attained by a broader mix of stimuli 
which is why they are subdivided further 93,103,104 into M2a, M2b, M2c and sometimes also 
M2d macrophages (Figure 2). M2a macrophages get activated upon stimulation with IL-4 
and/or IL-13 and are IL4Rα-dependent. IL-4 is secreted by granulocytes, such as basophils and 
mast cells, in response to injury or the occurrence of parasites or fungi and signals through 
STAT6. It further induces Arginase-1 expression which converts L-arginine to ornithine and 
urea, precursors of polyamines and collagen, and thus supporting the production of 
Figure 2: Diversity of macrophage activation represented by a colored wheel. Macrophages can quickly 
change between activation states depending on the factors they are exposed to which is illustrated here by a 
colored wheel with flowing transitions. The cells “between” the defined states represent macrophages that 
share properties or are in a transitional phase and are therefore difficult to classify. The main pro-inflammatory 
state is shown by M1 macrophages, normally induced by TH1 responses or infection and cytokines such as 
TNF and IFN. M2 macrophages are more diverse with anti-inflammatory, immune suppressive and pro-
tumoral properties and have been subdivided further: M2a are similar to wound-healing macrophages and need 
IL-4/IL-13. M2b and M2c are similar to regulatory M2-like macrophages and induced by TLR or IL-1R 
ligands and immune complexes; IL-10, TGF-β and glucocorticoids, respectively. M2d macrophages arise upon 
adenosine or IL-6 stimulation. TAMs are a heterogenous population and share characteristics of different 
activation states dependent on the TME, demonstrated here by the colors between other activation states. 
Adapted from reference #94.   
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extracellular matrix components 105 and upregulates mannose receptor CD206 90. Also, IL-4 
and IL-13 stimulated macrophages show decreased killing capacity compared to M1 
macrophages 94. M2b macrophages get activated in response to immune complexes and TLR 
ligands or IL-1R ligands. The recognition of immune complexes by Fc receptors recruits 
tyrosine kinase Spleen tyrosine kinase (Syk) and activates phosphoinositide 3-kinase (PI3K). 
It has also been shown that ligation of FcγRs on macrophages using Abs increased IL-10 
production in response to LPS 106,107. M2c macrophages are activated by IL-10, glucocorticoids 
and TGF-β. Glucocorticoids are known immune suppressive agents 108 which diffuse through 
the membrane of macrophages binding the glucocorticoid receptor- α and thus activating IL-
10 production 109. M2d activation appears after exposure to IL-6 and adenosine 103,110,111 leading 
to an angiogenic switch including vascular endothelial growth factor (VEGF) expression in an 
IL-4Rα-independent way 112,113. Recently, it has also been shown in human monocytes that M-
CSF gives rise to M2-like cells with high IL-10 production 98. 
 M2 macrophages express immune-suppressive and -modulatory cytokines, such as IL-10 and 
high levels of Arginase-1 (Arg-1) that depletes arginine from the surrounding and thus 
inhibiting T cell proliferation. IL-10 has been shown to enhance levels of IL-4R on the cell 
surface and thus making macrophages more susceptible to IL-4 and IL-13 signaling resulting 
in M2a polarization in a STAT3-dependent way 114. Furthermore, chitinases and chitinase-like 
molecules, YM1 (also known as CHI3L3) and YM2, resistin-like molecule-alpha (RELMa, 
also known as FIZZ1) are upregulated. Through the expression of these molecules these 
macrophages are suggested to be involved in the degradation of chitin-containing surfaces of 
parasites and fungi and that they play a role in matrix reorganization and wound healing by 
their matrix-binding ability 94. This type of macrophages has been connected to experimental 
asthma in mice and to be the mediators of tissue fibrosis in chronic schistosomiasis due to their 
malfunctioning regulation of matrix-enhancing possibilities 94. Tumor-associated macrophages 
(TAMs) are also considered as M2-like macrophages as they are immune suppressive and pro-
tumorigenic but are difficult to classify in any of the macrophage subpopulations as they differ 
between tumors. 
Taken together, the classification of macrophages into subgroups dependent on their functions 
or cytokines they respond to is difficult due to their complexity and diversity, especially in vivo. 
Also in humans, macrophages are very plastic cells and transcriptome analysis of differently 
stimulated human peripheral blood monocyte cell (PBMC)-derived macrophages revealed a 
plethora of macrophage subpopulations 115. Macrophages need to be discussed in the context 
they are studied in. Regardless of which phenotype the cells have when entering a new tissue 
or situation, they will adapt and change their polarization quickly to what is required there. 
Further effort needs to be put into exploring and understanding the whole capacity of 
macrophages.  
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1.3.2.4 Metabolic macrophage polarization 
Metabolic processes are complex, and the numbers of metabolites can easily run into the 
thousands. The last decades, metabolism got more attention in the field of immunology as it 
has been demonstrated that immune cells not only change their metabolic program in response 
to nutrients and oxygen availability but also upon activation and engagement of PRRs. In the 
1960s, phagocytosis in leukocytes has been connected to increased oxygen consumption and 
glycolysis whereas alveolar macrophages were described to use oxidative phosphorylation 
when phagocytosing 116,117. In 1970, Hard investigated metabolic processes specifically in 
macrophages and found that activated peritoneal macrophages show higher levels of glycolysis 
and lower levels of oxygen consumption 118. Stimulation of macrophages with LPS shifts their 
metabolic program to increased glycolysis leading to a pro-inflammatory phenotype including 
IL-1β secretion 119,120 and also IFN-γ stimulation changes their metabolism 89. In 2000, Mills 
et al. discovered important differences in the metabolism of M1 and M2 macrophages: M1 
macrophages consume arginine for the production of NO required for pathogen killing; M2 
macrophages use arginine to produce urea, polyamines and ornithine that are needed for repair 
and wound healing processes, such as collagen biosynthesis 91 121. Therefore, the polarization 
state of macrophages cannot only be found in gene expression and surface markers but also in 
their metabolic programming; which is why the field of immunometabolism got tremendous 
interest in the recent years.  
The shift towards enhanced glycolysis in LPS-activated macrophages is called “Warburg 
effect”. Otto Warburg detected increased glycolytic activity in tumor cells under aerobic 
conditions even though mitochondrial oxidative phosphorylation is more efficient regarding 
ATP production. However, instead of entering the tricarboxylic acid cycle and subsequent 
oxidative phosphorylation (OXPHOS), pyruvate was converted to lactate because lactic acid 
fermentation generates additional metabolites to support proliferation 122. Furthermore, lactate 
acid as well as acidic pH has been shown to polarize macrophages towards the tumor-
supporting M2 macrophage with increased VEGFA and Arginase-1 expression 123,124. In 
activated pro-inflammatory M1 macrophages the same shift from OXPHOS towards glycolysis 
has been observed, similar to the Warburg Effect. This has also been demonstrated in other 
immune cells, such as neutrophils as they rely on aerobic glycolysis for ATP production and 
only consume oxygen for the production of hydrogen peroxide (H2O2) needed for killing 
125,126. 
Classically activated M1 macrophages usually need rapid energy sources for efficient pro-
inflammatory responses. Therefore, they upregulate glycolytic processes to quickly gain 
energy in form of ATP. M1 macrophages have been shown to have a “broken” Krebs cycle 
which leads to the accumulation of Krebs cycle intermediates citrate and succinate 127. Citrate 
is further important for the production of NO, ROS and prostaglandins as inflammatory 
mediators 119. In contrast, the accumulation of succinate induces IL-1β secretion. High 
succinate concentrations activate hypoxia-inducible factor 1-alpha (HIF-1α) that directly 
induces pro-IL-1β expression by binding to the IL-1β promoter. The NACHT, LRR and PYD 
domains-containing protein 3 (NALP3) inflammasome, encoded by the NLRP3 gene, can also 
be activated through enhanced glycolysis 120,128. Also in human M1 macrophages increased 
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glycolysis correlates with an inflammatory phenotype 129. Taken together, all these processes 
supply cells with rapid energy and products they need to exert their inflammatory activity. In 
contrast, alternatively activated M2 macrophages rely on mitochondrial respiration and obtain 
their energy from fatty acid oxidation and oxidative metabolism 121.  
Immunometabolism is also approached in other immune cells, such as T cells and NK cells. 
Activated T cells undergo metabolic reprogramming and increase aerobic glycolysis 130,131 and 
also NK cells enhance glycolysis levels and OXPHOS after activation with IL-12 and IL-15 in 
vitro, in mice as well as in humans. However, chronic exposure of human NK cells to IL-15 in 
vitro decreased their metabolic processes 132.  
1.3.3 Myeloid- derived suppressor cells 
Myeloid- derived suppressor cells (MDSCs) are cells with immunosuppressive potential that 
can strongly inhibit T cell responses but also innate immune responses by affecting cytokine 
production by macrophages. MDSCs are no defined population of cells but a phenotypically 
heterogeneous group that consists of immature myeloid cells (IMC). IMCs occur during normal 
myelopoiesis in the bone marrow but usually migrate to the periphery and differentiate into 
macrophages, DCs or granulocytes. However, under certain pathological circumstances the 
differentiation of IMCs is blocked, and these cells are expanding and are then called MDSCs. 
They express a plethora of immune inhibiting factors, such as Arginase-1, iNOS and enhance 
production of ROS and NO. There are two main MDSCs subtypes that are distinct in their 
surface receptor expression: In mice, granulocytic MDSCs (CD11b+ Ly6G+ Ly6Clow) and 
monocytic MDSCs (CD11b+ Ly6G- Ly6Chigh); in humans, CD11b+CD14- CD33+  or LIN- 
HLA-DR- CD33+ 133. MDSCs in the pathological condition of cancer is further described in 
chapter 1.5. 
1.4 SCAVENGER RECEPTORS 
Initially, scavenger receptors (SR) have been defined by their ability to bind and internalize 
modified low-density lipoprotein in 1979 by Goldstein and colleagues 134. Since then, many 
other ligands have been defined and SR are known to bind polyanionic (negatively charged) 
molecules and contain highly conserved scavenger receptor cysteine-rich (SRCR) domains 135. 
SR are PRRs on phagocytes that can bind modified self, such as acetylated or oxidized low 
density lipoprotein (LDL) 134 and bacterial structures, such as LPS by gram-negative bacteria 
136 and lipoteichoic acid by gram-positive bacteria. SR are classified into eight different groups 
based on their multi- domain structure (class A – H) 135,137; however, the structures between the 
groups are very heterogeneous.  
Based on their binding to LPS, SR have been suggested to be involved in anti-bacterial 
responses and to play a crucial role in the host defense against pathogens. They can bind and 
ingest bacteria directly such as Escherichia Coli 138 and SR-deficient mice implicated to be 
more susceptible to infection with Listeria monocytogenes, herpes simplex virus type-1 139 or 
Staphylococcus aureus 140. Members of the scavenger receptor class-A (SR-A) family are 
trimeric transmembrane glycoproteins 141. Several SRs are involved in the clearance of 
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apoptotic cells, such as SR-A family members and CD36 142, and it has been shown that SR-A 
are crucial for the internalization of extracellular double stranded RNA 143,144. Furthermore, 
SR-A receptors have been revealed to bind ligands through their collagenous domain of the 
receptor 145,146 and their short cytoplasmic domain to be crucial for trafficking and 
internalization 147,148. As scavenger receptor MARCO is the central topic of this thesis it will 
be described in detail below.  
1.4.1 Scavenger receptor MARCO 
Scavenger receptor MARCO (macrophage receptor with 
collagenous structure) was cloned by Karl Tryggvason at 
Karolinska Institutet in 1995. It is a 210 kDa trimeric 
membrane bound type II glycoprotein with collagenous 
structure belonging to the SR-A family. The receptor 
consists of five regions (Figure 3): a N- terminal short 
cytoplasmic domain, a transmembrane domain, a spacer 
domain between collagenous structure and membrane, 
the collagenous structure that is involved in trimerization 
and the C-terminal group A-type SRCR region 77,149 
which has been implicated in ligand binding 150. 
MARCO expression is restricted to some macrophage 
subtypes and is constitutively expressed on MZMs in the 
spleen, peritoneal macrophages, medullary macrophages 
in the lymph node 149 and on alveolar macrophages 151. 
In humans, highest MARCO expression is found in lymph nodes, liver and on alveolar 
macrophages 152,153. Even though it is not expressed on other macrophage subtypes in steady 
state, MARCO can be upregulated upon treatment with bacteria or LPS stimulation on liver-
resident Kupffer cells 154, DCs 155, red pulp macrophages 154 and other macrophages 156. LPS-
induced MARCO upregulation in splenic macrophages is Toll like receptor 4 (TLR4)-
dependent and can occur in a MyD88-dependent or MyD88-independent manner 157. Also SR-
A has been reported to be upregulated on murine macrophages upon LPS stimulation 158 and 
even though SR-A and MARCO have structural similarities, they act differently on the 
macrophage: Ligation of SR-A inhibits IL-12 production, whereas engagement of MARCO 
supports IL-12 release 81,159.  
In lymphoid organs, MARCO expressing cells are strategically well-located aligning the 
marginal zone in the spleen and the medullary cord of lymph nodes which highlights MARCO 
as a crucial receptor for clearance of blood- and lymph-borne pathogens and apoptotic cells 77. 
Defects in clearing apoptotic cells bears a higher risk to develop autoimmune diseases, such as 
SLE 160. Besides the disease-characteristic presence of anti-DNA Abs, SLE patients also have 
autoantibodies against MARCO 44 and when injecting apoptotic cells into MARCO-deficient 
mice they develop higher levels of anti-DNA Abs 44. However, it is not known whether these 
autoantibodies are initiators or symptoms of the disease. Other known ligands for MARCO are 
Figure 3: The structure of scavenger 
receptor MARCO. Schematic 
representation of its five domains. 
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oxidized LDL 134, E.Coli and S. aureus 78. MARCO can deliver CpG DNA to the endosomal 
TLR9 and is required for TLR9–mediated IL-12 and NO production in response to CpG 
oligonucleotides in microbial DNA 161. Lacking MARCO expression on splenic MZMs causes 
the disruption of functional MZ structure and impairs responses to TI Ag 162. The lack of 
MARCO also reduces the number of peritoneal macrophages in MARCO-deficient mice 162. 
When non-myeloid cells are transfected to express MARCO they change their cell morphology 
obtaining large lamellipodia-like structures and dendritic-like membrane extensions 163. Also 
the transfection of macrophages with SR-A results in morphological changes including 
increased spreading 164. This results in decreased migration which is important for successful 
particle engulfment 163.  
So far, little is known about signal transduction after engagement of MARCO. The receptor 
has a very short cytoplasmic domain and does not contain any classical sequences that are 
associated with internalization, phosphorylation or clustering. In microglia, MARCO has been 
reported to interact with formyl peptide receptors which are G-protein-coupled PRRs that 
recognize a broad variety of ligands, derived from pathogens but also host cells 165. Further, 
MARCO mediates inflammatory cytokine production upon Mycobacterium tuberculosis 
infection through TLR2 and CD14 166 and enhances TLR2- and nucleotide-binding 
oligomerization domain 2 (NOD2)-dependent signaling during S. pneumoniae colonization in 
the nasopharynx of mice. Thus, increasing NF- κB activation and enhancing pro-inflammatory 
molecule production, such as TNF-α, IL-1β, and IL-6 167. Additionally, ligand binding and 
internalization by MARCO increases cytosolic NOD2 and NALP3 inflammasome as well as 
endosomal TLR3 signaling. At the same time, MARCO ligand internalization diminishes 
TLR4-dependent responses 168. When targeting MARCO with monoclonal Abs, MARCO+ 
peritoneal macrophages release high levels of ATP comparable to the levels after LPS 
stimulation which we demonstrate in this thesis in paper I 169. Extracellular ATP is seen as pro-
inflammatory agent and leads to M1 macrophage polarization 170. In contrast, MARCO inhibits 
early inflammatory responses to influenza A virus and MARCO-deficient mice show increased 
neutrophil influx and better survival 171. The anti-MARCO Ab clone used in the studies 
included in this thesis has been demonstrated to block ligand binding as it suppressed the uptake 
of FITC-labelled E.coli by MARCO expressing/transfected CHO cells 156. This suggests that 
binding of anti-MARCO Ab to MARCO could initiate Ab uptake in the same way as it initiates 
the uptake of MARCO after bacteria binding. By using cells expressing truncated versions of 
MARCO and measuring the uptake of FITC-labeled E.coli the bacteria binding site was found 
to be located immediately proximal to the cysteine residues of the SRCR domain 149. This is 
supported by Novakowski et al. also indicating that the SRCR domain of MARCO is important 
for ligand binding unlike SR-A that binds its ligands through its collagenous structure 145,146. 
Also, the SRCR domain of MARCO is required for the induction of pro-inflammatory 
signaling via TLR2 172 and increasing TLR2 and CD14 signaling in response to S.  pneumoniae 
167.  
Interestingly, MyD88-dependent TLR ligation and incubation with tumor lysate induces 
MARCO expression on DCs 173–175 which in turn enhances their phagocytic capacity 173. 
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However, another study by Granucci and colleagues shows that MARCO expression in DCs 
leads to actin cytoskeleton rearrangement similar to mature DC phenotype and a decrease in 
phagocytosis 155. Targeting tumor lysate-conditioned MARCO+ DCs with monoclonal Abs 
results in enhanced motility and anti-tumor activity in the B16 melanoma mouse model. 
Moreover, these anti-MARCO Ab targeted DCs lose their dendritic- like phenotype 174,176. The 
follow up study in MARCO-deficient tumor-pulsed DCs showed increased migratory 
capacities toward the lymph nodes and enhanced anti-tumor T cell responses after injection 
into tumor-bearing mice 176. This is supported by another study demonstrating that MARCO-
deficient pulmonary DCs acquired increased migratory capacities towards the lymph nodes 
upon allergen exposure leading to augmented airway inflammation 177. In contrast, alveolar 
macrophages require MARCO expression for effective lung defense 178.  
In humans, MARCO (hMARCO) has been identified to be similar to murine MARCO in 68% 
amino acid sequence identity and 77% similarity 149. In line with murine MARCO, hMARCO 
also binds E.coli and S.aureus; however, it was not found to bind modified LDL as its murine 
counterpart. Highest hMARCO expression in the human body was found in liver, lymph nodes 
and lung 152. In patients that died from sepsis, widespread MARCO expression was found in 
several human tissues which supports previous findings in mice that MARCO can be 
upregulated upon bacterial infections 149,156. MARCO has also been found on the immune 
suppressive TAM subtype in human non‐small cell lung cancer (NSCLC) 179. Within studies 
including in this thesis, we also found MARCO expression in other human cancers correlating 
with poor prognosis, including human melanoma, breast cancer and pancreatic cancer patients 
(paper II and IV). Interestingly, a recent study by Sun and colleagues reports a connection 
between MARCO and hepatocellular carcinoma (HCC) patients as they find MARCO 
expression correlates positively with patient survival rates. Fewer MARCO+  macrophages 
were inside the tumor compared to peritumoral areas and MARCO expression decreases with 
tumor progression – correlating highest MARCO expression in healthy controls and lowest 
expression in HCC patients with metastasis 180.  
1.5 THE TUMOR MICROENVIRONMENT 
Tumors are complex and heterogeneous tissues that consist of many different components 
besides malignant cancer cells. The hallmarks of cancer progression and their characteristics 
were defined by Hanahan and Weinberg and include high replicative potential, genome 
instability, persisting growth but resisting apoptosis signals, abnormal metabolic processes, 
avoiding immune destruction, persistent angiogenesis, invasion and metastasis 181. However, 
tumor cells do not operate alone in the complex multi-level process of tumor initiation, 
progression and metastasis spreading. Besides malignant cells there are many non-malignant 
cells involved, such as pericytes, adipocytes, cancer-associated fibroblasts (CAFs), endothelial 
cells and immune cells. In many solid tumors desmoplasia occurs, resulting in dense fibrosis 
and pancreatic cancer is one of the most extreme tumor types with fibrotic stroma.  
The interaction between tumor and non-malignant cells defines the tumor microenvironment 
(TME) and consists of a complicated network between growth factors, cytokines, chemokines 
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but also inflammatory and matrix remodeling molecules 182. Tumor cells organize their own 
microenvironment and tumor-derived mediators recruit other cell types to support their growth 
182. In the last decades, tumor-promoting inflammation and the escape from immune control 
became a hallmark of cancer 181 after Rudolf Virchow proposed a link between cancer and 
inflammation already in 1863. Immune cells are known to infiltrate most types of cancers; T 
and B lymphocytes, NK and NKT cells, MDSCs, tumor-associated neutrophils (TAN), DCs 
and TAMs are present. Most of these cells show an immunosuppressive phenotype that 
supports tumor growth and inhibits efficient anti-cancer immune responses (Figure 4). 
Especially TAMs play an important role in tumor-promoting inflammation and have been 
associated with poor prognosis in many human cancers 183.  
 
Figure 4: Illustration of the immune suppressive tumor microenvironment.  The tumor microenvironment 
(TME) is very diverse and consists of many different cell types. Immune cells are recruited to the tumor site, re-
programmed and suppressed by tumor-derived mediators. B cells, T cells, tumor-associated macrophages (TAMs), 
myeloid-derived suppressor cells (MDSC), neutrophils and dendritic cells are present. Besides immune cells, there 
are blood vessels, lymphatic vessels, pericytes, cancer-associated fibroblasts (CAFs) in the TME as well as hypoxic 
and necrotic areas, all supporting the tumor and its immune suppressive environment in their own ways.   
The regulation of tumor growth and modulation of TME by the immune system has been a 
central question in the field of immunology already for years. It started with Burnet and Thomas 
when they proposed the “cancer immunosurveillance hypothesis” stating that immune cells 
were required for hampering cancer progression 184,185. With the rise of improved mouse 
models of immunodeficiencies, immunologists performed additional experiments and further 
defined the involvement of immune cells in shaping the immunogenicity of tumors. 
Interestingly, immunocompetent mice had lesser immunogenic tumors (“edited”) than mice 
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lacking an intact immune system (“unedited”). This uncovered the double-sided role of 
immune cells in tumor-fighting and tumor-promoting actions 186 and gave rise to the “cancer 
immunoediting hypothesis”.  Today we know that the immune system cannot only combat and 
fight tumors but also supports tumor growth on different levels in dynamic processes 187,188. 
The immunoediting process of tumor cells can broadly be divided into three distinct phases: 
elimination, equilibrium and escape. However, malignant cells may skip phases dependent on 
their external influences. In the first step, the “elimination” phase, innate and adaptive immune 
cells collaboratively destroy and eliminate tumor cells. This can be due to the recognition of 
DAMPs from dying tumor or host cells or the activation of DCs through type I interferons and 
subsequent activation of adaptive immunity. The “equilibrium” stage is entered by tumor cells 
that survived the elimination phase. Here, tumor cell growth is controlled by the immune 
system and tumor cells are in a state of dormancy. This phase`s duration is very variable and 
can take up to years before tumor cells pass over to the escape phase. Once the tumor cells 
overcome equilibrium, they are entering the final “escape” phase. By that time, tumor cells 
acquired the capacity to evade the immune system and are “invisible” to the immune cells 
resulting in tumor cell outgrowth. This can be reached through the decrease or loss of tumor 
antigens or enhanced resistance against cytotoxic mechanisms. Furthermore, tumor cells can 
modulate the TME to become immune suppressive and thus, promoting their own survival and 
growth187,188. For instance, one way to escape the destruction by phagocytosis is the 
transmembrane protein CD47 which acts as “don`t eat me signal”. CD47 binds its ligand signal 
regulatory protein-alpha (SIRP-α) expressed by TAMs and DCs and thus inhibits phagocytosis 
of the tumor cell. High intratumorally expression of CD47 has been correlated with bad 
prognosis in several cancers, such as breast cancer, and blocking of CD47 results in enhanced 
tumor cell killing by TAMs 189. 
Some of the immune suppressive properties immune cells can exert in the TME are listed here: 
Tregs are defined by their expression of CD25 and transcription factor FoxP3, elicit 
immunosuppressive functions through the release of IL-10 and TGF-β and cytotoxic T-
lymphocyte antigen 4 (CTLA-4) which is a negative regulator and inhibits further initiation of 
potent anti-tumor immune responses 190,191. Therefore, the presence of Tregs is associated with 
bad prognosis. Also tumor-infiltrating B cells have been found to be pro-tumorigenic as B cell 
depletion slowed down tumor growth and metastases formation to the lung 192. The discovery 
of regulatory B cells producing IL-10 and TGF-β confirmed the immunosuppressive capacity 
of B cells inside the tumor and regulatory B cells help CD4+ T cells to differentiate into tumor-
promoting Tregs 
193. CAFs can secrete many growth factors and cytokines, including TGF-β 
which supports epithelial-mesenchymal transition (EMT) in tumor cells and thus promoting 
metastases spreading to distal tissues 194,195. In addition, vascularization is required for tumor 
growth and immune cells can release angiogenic factors supporting neovascularization within 
the tumor. VEGF is the prevailing pro-angiogenic factor in the TME that initiates new vessel 
formation characterized by abnormal structures, such as diffuse branching and irregular vessel 
lumen. Intratumor vascularization is often also leaky hence supporting the intravasation of 
tumor cells 196.  
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As described in chapter 1.3.3, MDSCs are defined as potent inhibitory immune cells within the 
TME  in many cancers and it has been demonstrated that they can also differentiate into TAMs 
197. In healthy individuals, there are only few of these immature myeloid cells present. In mice, 
there are usually 2- 4% in the spleen; however, in tumor-bearing mice this highly suppressive 
cell type can expand and reaches 20-40% of all splenic cells. Factors that have been shown to 
result in MDSC expansion are prostaglandins, M-CSF, GM-CSF, IL-6 and VEGF – all factors 
that are present in most tumors. On the transcriptional level, STAT3 was identified to be the 
main regulator of MDSC expansion. To get activated, MDSCs need to experience IFN-γ, IL-
4, IL-13 or TGF-β 133 and characteristically for MDSCs is the increased expression of Arginase-
1 and iNOS. These enzymes consume L-arginine, thus inhibiting T cell proliferation 198 and 
the generation of NO reduces T cell activation by inducing apoptosis 133,199. Further, MDSCs 
support Treg differentiation and promote the formation of an immune suppressive TME 
133,200. 
In relation to TAMs, it has been shown that the adoptive transfer of freshly isolated MDSCs to 
tumor – bearing mice results in differentiation of MDSCs to TAMs. These TAMs were able to 
induce T cell apoptosis in vitro in an Arginase-1 and NO-dependent matter 201. 
All these immune cells contribute to the immune suppressive TME which inhibits anti-tumor 
responses and at the same time promotes tumor growth. In the next chapter, I will further focus 
on TAMs as the main player in this thesis, their role in the TME and some processes of 
particular interest for understanding the studies included in this thesis. 
1.5.1 Tumor-associated macrophages 
Macrophages in general are a very heterogenous cell population and difficult to classify. 
TAMs are even more complex and their presence is often correlated with poor prognosis 202,203. 
They can be of pro-inflammatory nature inducing potent anti-tumor responses resulting in 
the eliminiation of tumor cells. However, TAMs are mostly of a M2-like immune suppressive 
phenotype with pro-tumor capacities supporting tumor growth by promoting angiogenesis, 
tumor cell proliferation, tissue remodeling and metastases. 
1.5.1.1 Origin of tumor-associated macrophages 
The origin of TAMs is still disputed and TAMs were shown to originate from tissue- resident 
macrophages, circulating bone marrow-derived monocytes but also from M-MDSC that are 
recruited to the tumor site by mainly CCL-2 203,204 and CCL-5 205. These chemokines can be 
released by tumor cells, endothelial cells, fibroblasts but also TAMs 205. Additionally, CCL3 
(macrophage inflammatory protein (MIP)1 alpha), CCL4 (MIP1 beta), CXCL12 (stromal cell-
derived factor 1 alpha), IL-6, CSF-1 and VEGF-α are capable of recruiting monocytes to the 
tumor site in different mouse models 206. 
In mammary adenocarcinoma, Ly6ChiCX3CR1
low monocytes have been identified as the main 
precursors of TAMs 207. This is consistent with the findings of Franklin and colleagues 
demonstrating that circulating Ly6C+CCR2+ monocytes replenish TAMs in the MMTV-PyMT 
tumor model 208. Also, the spleen has been identified as a reservoir of Ly6Chigh monocytes that 
can be recruited to tumors via CCL2/CCR2 signaling and further differentiate into TAMs 209. 
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However, TAMs can also originate from tissue-resident macrophages, such as in gliomas with 
yolk sac-derived progenitors 210 or even represent a mixed pool of tissue-resident and 
inflammatory monocyte-derived TAMs as reported by Zhu et al. In murine pancreatic ductal 
adenocarcinoma (PDAC) models, Zhu and colleagues identified TAMs originated from 
pancreas-resident macrophages and others from inflammatory monocytes. Interestingly, the 
tissue-resident macrophages arose from embryonic stem cells and proliferated during tumor 
progression. Comparing these two TAM subpopulations by mRNA sequencing, only the 
embryonic-derived tissue-resident TAMs showed an increased pro-fibrogenic phenotype 
suggesting a role in remodeling the extracellular matrix while the monocyte-derived TAMs 
showed enhanced gene expression related to Ag presentation 211. Furthermore, MDSCs can 
quickly differentiate into immune suppressive TAMs when they infiltrate tumors. Hypoxia 
leads to dramatic changes in MDSCs via HIF-1α, associated with the upregulation of Arg-1 
and iNOS and differentiation into immune suppressive TAMs 197. A recent study proposed the 
differentiation of MDSCs to TAMs is caused by hypoxia – mediated decrease of STAT3. 
However, they found it to be independent on HIF-1α but downregulation of STAT3 resulted in 
differentiation of M-MDSCs to TAMs 212. 
1.5.1.2 The role of tumor-associated macrophages in the tumor 
TAMs are one of the most abundant immune cell in most cancers and exert numerous functions 
within the TME to affect tumor growth: On one hand they can inhibit tumor growth and 
eliminate malignant cells, but on the other hand they also support tumor progression by 
expression of immune suppressive cytokines, degradation of extracellular matrix, stimulation 
of angiogenesis 213 or even promote tumor cell intravasation to form distant metastases 214. For 
this, tumor cells express CSF-1 to stimulate TAMs and in turn, macrophages release epidermal 
growth factor (EGF), a known tumor cell growth factor.  
Mostly, TAMs have an activation state that is towards the alternatively activated and anti-
inflammatory macrophage, with tumor-promoting capacities (also referred to as immune 
suppressive M2 phenotype), incapable of tumor cell killing, antigen presentation or T cell 
activation. This is due to TME-derived agents, such as IL-4, TGF-β and IL-10 that all favor an 
immunosuppressive TME (Figure 5). Thus, TAMs pick up a tumor-supporting phenotype, 
produce IL-10 and TGF-β by themselves, express Programmed death-ligand 1 (PD-L1) which 
suppresses T cell activation 215 and the production of TGF-β supports EMT of tumor cells that 
is needed for them to enter the circulation and metastasize 194,195. Macrophages are known to 
uptake apoptotic cells but the uptake of apoptotic cells simultaneously diminishes their 
production of pro-inflammatory cytokines but instead supports anti-inflammatory cytokine 
production 216,217. This suggests one possible way of immune evasion by tumor cells as like this 
the cytotoxic activity by TAMs against tumor cells is inhibited. Further, it has been shown that 
autoantibodies produced by B cells within the tumor drives TAM polarization and the 
engagement of activating FcγR promotes inflammation-associated tumor progression 
including tumor-angiogenesis 218,219. New blood vessel formation as well as extracellular 
matrix remodeling further promotes cancer cell spread 202. 
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Figure 5: Tumor-promoting functions of TAMs in the tumor microenvironment (TME). Tumor-associated 
macrophages (TAMs) have various tumor-supporting functions in the TME. They are skewed towards an immune 
suppressive and pro-tumoral phenotype by tumor-derived mediators or produced by other cells inside the TME, 
such as IL-4, IL-10, TGF-β, adenosine or hypoxia. In turn, they upregulate a lot of immune inhibiting factors, such 
as IL-10 and TGF-β by which effector T cells, DCs and NK cells are inhibited to exert their anti-tumoral properties 
and regulatory T cells are instead supported. Disruption of extracellular matrix (ECM) by metalloproteinases 
(MMP), the support of epithelial to mesenchymal transition (EMT) of tumor cells and enhanced angiogenesis lead 
to increased tumor growth and risk of metastasis formation.  
Recently, Yang and colleagues reviewed different TAM populations within the same tumor 
and how their tumor-supporting functions differ between their microenvironments. For this, 
they subdivided the tumor area into cancer cell invasion part, so-called “tumor nests” where 
the tumor cells are most dense, the hypoxic and the perivascular niche 214. TAMs can support 
cancer cell invasion by the production of matrix metalloproteinases (MMP) for remodeling the 
extracellular matrix (ECM) and supporting tumor cell migration through disrupting basement 
membranes 214. Moreover, the depletion of macrophages delayed the progression from 
preinvasive lesion to invasive carcinoma supporting the finding that these TAMs play a role in 
tumor cell invasion 220. “Tumor- nests” are areas in the tumor defined by highest density of 
malignant cells. There is controversial data available whether high numbers of TAMs in these 
so called “tumor-nests” correlate with good or bad prognosis, it most probably depends on the 
type of cancer. For instance, high numbers correlate with good prognosis in endometrial cancer 
but with reduced prognosis in malignant melanoma 214. The ECM consists mostly of non-
malignant cells, such as immune cells, endothelial cells, pericytes and fibroblasts as well as 
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ECM molecules including collagen, fibronectin and laminin. Surprisingly, the TAM phenotype 
is also regulated by components of the ECM such as fibronectin and laminin and this finding 
is supported by another study that demonstrated decellularized ECM from human tumors 
polarize macrophages towards an immune suppressive phenotype with enhanced levels of IL-
10 and TGF-β 221,222. Hypoxic areas are characteristic for tumors, they have very little oxygen 
and are distant from tumor vessels and can be detected by staining for hypoxic cell markers, 
such as pimonidazole (PIMO) 214. TAMs in hypoxic areas support blood vessel formation and 
express indoleamine 2, 3 – dioxygenase (IDO) that inhibits CD8+ T cell proliferation and 
supports Tregs. Hypoxia induces a metabolic switch to increased glycolysis resulting in the 
accumulation of lactate within these areas. Lactate has been shown to differentiate TAMs into 
a proangiogenic subtype with enhanced VEGFA expression 123,214,223 and moreover, inhibition 
of lactate reduced the number of proangiogenic TAMs and tumor growth 223.  
Perivascular TAMs support tumor angiogenesis, metastasis and are responsible for tumor 
relapse after therapies in some tumors. Furthermore, they are associated with markers that are 
expressed by M2 macrophages, such as MRC1 and CD163 and one specific receptor is 
Angiopoietin-1 receptor (TIE2), the main receptor for angiopoietins (protein growth factors 
required for the formation of blood vessels) 224. These TIE2-expressing perivascular TAMs are 
also called “TIE2-expressing monocytes/macrophages” (TEM) and De Palma et al. reported 
the requirement of these TEMs for tumor vascularization by injecting TIE2+ or TIE2- 
monocytes together with mouse mammary cancer cells. Tumors with TIE2+ monocytes had 
increased vascularization compared to cancer cells alone or cancer cells injected with TIE2- 
monocytes 225. The ligand of TIE2 is angiopoietin 2 (ANG2), an angiogenic factor expressed 
by activated endothelial cells and an increase in ANG2 supports tumor vascularization. The 
role of TEMs in tumor angiogenesis was confirmed by blocking TIE2/ANG2 signaling that 
decreased tumor vascularization dramatically and resulted in reduced tumor growth 226. Also, 
tumor-infiltrating TEMs from mouse tumors showed higher expression of several M2-like 
tumor promoting genes compared to other macrophages from the same tumor, such as Mmp9 
and VEGFA 227 and the frequency of TEMs positively correlates with micro-vessel density in 
human cancers, such as HCC 228. Furthermore, TEMs have been associated with interference 
of anti-cancer therapies and the relapse of primary lung and breast cancer mouse models after 
chemotherapy. These TEMs express VEGFA which stimulates re-vascularization and re-
growth of cancer cells as well as high levels of CXCR4 which ligand is CXCL12. After 
chemotherapy, CXCL12 is upregulated in the perivascular niche, thus recruiting TAMs to the 
perivascular area. Blocking of CXCR4 decreased numbers of M2-like TAMs after 
chemotherapy, especially the ones in close proximity to blood vessels, thus decreasing re-
vascularization and tumor re-growth 229. Interestingly, this CXCR4/CXCL12 axis and the 
recruitment of new infiltrating monocytes to the perivascular areas has also been reported in 
untreated tumors 230. When monocytes enter the tumor, tumor-derived TGF-β induces them to 
upregulate CXCR4 which then leads them through a chemotactic gradient to CXCL12-
expressing fibroblasts close to tumor blood vessel. Once they arrive there they become 
metastasis-supporting perivascular TAMs 230.  
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Harney et al. revealed the presence of cells that were named “tumor microenvironments of 
metastasis” (TMEM) which consist of TIE2+ VEGFA+ TAMs that are in direct contact with 
cancer and endothelial cells. The tumor cells in TMEMs show increased motility due to the 
overexpression of the invasive isoform of the actin-binding protein mammalian enabled 
(MENA) and at the site of TMEMs there is enhanced intravasation of tumor cells into the 
vessels monitored 214,231. In breast cancer patients, the frequency of TMEM positively 
correlates with the number of distant metastases compared to patients with only localized breast 
cancer 232.  
1.6 CANCER IMMUNOTHERAPY 
In some solid tumors, such as breast cancer, infiltrating immune cells can make up to 50% of 
the whole tumor 210. Inflammatory cells are recruited to the tumor site and initially exert anti-
tumor functions. However, the TME modulates the immune cells in a way that they become 
immune suppressive and support tumor progression. Therefore, immunotherapy is a way of 
harnessing the immune system to successfully fight malignant cells and eradicate the tumor. 
The aim is to unleash the immune system and reactivate innate and adaptive immune cells to 
carry out potent anti-cancer immune responses. This approach is an alternative to classic anti-
cancer treatments such as chemotherapy where tumors can become resistant for. 
Cancer immunotherapies are classified into active and passive therapy. The classification is 
based on the ability to (re-)activate the host immune system: Passive immunotherapy includes 
adoptively transferred T cells and the administration of tumor-targeting antibodies. Passive 
immunization does not induce memory responses but directly targets tumor cells or activates 
the immune system. In contrast, active immunotherapy includes anti-cancer vaccinations and 
checkpoint inhibitors. This leads to long-lasting anti-tumor immune responses and is called 
active because the engagement of the host immune system is required 233. 
T cell-targeting immune checkpoint inhibitors, such as anti-PD-1, PD-L1 or CTLA-4 Abs, are 
helping many cancer patients to reduce their tumor burden and improved overall survival. 
However, some patients develop resistances against immunotherapies which is mostly 
mediated through tumor-associated myeloid cells, including macrophages 234 and additionally, 
not all patients respond fully to immunotherapy 235. This can be due to escape mechanisms 
acquired by tumor cells, such as the loss of MHC-I and diminished antigen presentation 236. 
This would then suggest implementing more NK cell-based immunotherapies which could 
sense these MHC-I deficient cells.   
Targeting MARCO+ TAMs as possible anti-cancer immunotherapy has been addressed in this 
thesis in paper II, III and IV. Anti-MARCO Abs were used as monotherapy but also in 
combination with other immune checkpoint inhibitors. Therefore, immune cell targeting by 
monoclonal Abs and other immunotherapeutic approaches will be discussed here.  
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1.6.1 Antibody-mediated immunotherapy  
The use of monoclonal anti-MARCO Abs is a central topic of this thesis and the interaction 
with Fc receptors (FcR) is thematized in paper II and paper III, therefore, a short introduction 
is given here with specific focus on Fc γ receptors (FcγR).  
FcγR control a variety of immunological functions in innate as well as adaptive immune cells 
by binding the Fc domain of IgG antibodies. The IgG subclass is the most common Ab type 
found in the blood and is produced by plasma cells after class-switching. IgG subclasses are in 
mice, IgG1, IgG2b and IgG3 and depending on the mouse strain either IgG2a (BALB/c) or 
IgG2c (C57BL/6); in humans, IgG1, IgG2, IgG3 and IgG4 and the affinity and specificity of 
therapeutic Abs to different Fc receptors dramatically mediates their effector function. The IgG 
subclass determines the mediated function, such as secretion of cytokines and chemokines, 
cellular activation, antigen uptake and presentation or the selection of B cells during their 
development. IgG Abs are Y-shaped proteins from which the “arms” are called Fab regions 
consisting of a light and a heavy chain as well as a constant and variable region. The variable 
region gives the Ab its antigen specificity and binds to the encountered antigen through its 
complementarity determining regions (CDRs). The lower part of the Y-shaped protein is called 
Fc part, binds to Fc receptors, consists of two heavy chains and mediates immune cell activity 
by generating appropriate immune responses dependent on the antigen. 
FcR are divided into type I and type II FcR, depending on their binding stoichiometry and 
binding sites of the IgG Fc domain. Receptors of the type I group are related to the 
immunoglobulin receptor superfamily including FcγR, type II receptors belong to the family 
of C-type lectin receptors and include DC-SIGN (CD209) and CD23. For this thesis, type I 
FcR are of particular interest and will be described here in more detail.  
Dependent on their intracellular signaling domain, type I FcγR are divided into activating or 
inhibitory receptors. In mice, there are three activating Fc receptors, FcγRI, FcγRIII and 
FcγRIV and one inhibitory Fc receptor FcγRIIb. This is different in humans who have five 
activating Fc receptors, FcγRI (CD64), FcγRIIa (CD32a), FcγRIIc (CD32c), FcγRIIIa 
(CD16a), FcγRIIIb (CD16b) but also only one inhibitory Fc receptor FcγRIIb (CD32b). Upon 
Ab binding, activating FcγR signal through immunoreceptor tyrosine activation motifs 
(ITAMs) in their cytoplasmic domain (FcγRIIa and FcγRIIc) or in the associated FcRγ chain 
(FcγRI, FcγRIIIa); in contrast, the inhibitory FcγRIIb transduces signals via the 
immunoreceptor tyrosine inhibition motif (ITIM) in its intracellular domain. Most of the 
hematopoietic cells express activating and inhibiting FcγR so the ratio of these will define the 
immunological response. Monocytes and macrophages express all FcγR whereas DCs express 
activating FcγRI and FcγRIII and the inhibitory FcγRIIb. B cells only express the inhibitory 
FcγRIIb and NK cells only the activating FcγRIII.  
FcR have been implicated to be important in cancer therapy as they control Ab-dependent 
therapy responses. FcγRIIb-deficient mice are more sensitive to monoclonal Ab (mAb) therapy 
and show increased cytotoxicity as the inhibiting receptor has been depleted 237. Furthermore, 
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FcγRIIb is required for agonistic activity of mAb immunotherapy targeting CD40 through 
crosslinking the receptors 238 but diminishes the efficacy of anti-CD20 mAb rituximab targeting 
B cells. As FcγRIIb is involved in the internalization of CD20/anti-CD20 complexes it inhibits 
ADCC of malignant B cells 239. Furthermore, humanized FcR mice demonstrated the 
requirement of FcγRIIIa on macrophages for anti-CD20 mAb – mediated cytotoxicity 240. 
Taken together, this demonstrates that for the design of new Ab based anti-cancer therapies the 
binding capacity of Fc parts to different FcR classes needs to be carefully evaluated. 
Moreover, FcγR are also connected to macrophage polarization and activation: IL-4 has been 
reported to upregulate the inhibitory FcγRIIb receptor on M2 macrophages 85 and IFN-γ as 
stimulator for M1 macrophages downregulates FcγRIIb but promotes FcγRI expression on 
myeloid cells 241. FcγRIIb-deficient macrophages show an increased inflammatory phenotype 
242 and engaging activating receptors on macrophages by immune complexes leads to increased 
pro-inflammatory cytokine release 243. However, the simultaneously stimulation of FcγRIIb 
inhibits the immune response 244, a modulatory pathway to avoid overactivated cells. Also, the 
ligation of activating FcγR in combination with TLR4 engagement leads to anti-inflammatory 
macrophage phenotype 245. 
1.6.2 Targeting T cells 
Immune checkpoint inhibitors were discovered for anti-cancer therapy to remove the brakes on 
T cells and to re-activate them. In 1996, James P. Allison demonstrated that Abs against the 
inhibitory receptor CTLA-4 on T cells suppresses tumor growth by promoting T cell 
reactivation and anti-tumoral properties 246. This was the first time shown that CTLA-4 
blocking can treat tumors in murine tumor models. However, it took another 15 years until the 
first anti-CTLA-4 Ab (ipilimumab) got approved by the Food and Drug Administration (FDA) 
as first immune checkpoint inhibitor for the treatment of stage IV melanoma patients in 2011 
247. Anti-CTLA-4 Abs were the breakthrough in the immunotherapy field as for the first time 
immune-checkpoint blockade enhanced advanced – stage cancer patient survival. Ipilimumab 
was the first treatment that showed increased overall survival in advanced stage melanoma 
patients in a phase III clinical trial 248. Other FDA approved immune checkpoint inhibitors are 
anti- PD-1 and anti-PD-L1 Ab.  
CTLA-4 is expressed on activated T cells and works as a negative regulator. Upon the 
recognition of Ags in context of MHC complexes on APCs and the engagement of co-
stimulatory receptor CD28, T cells get activated and upregulate their CTLA-4 expression. The 
inhibitory receptor CTLA-4 and the co-stimulatory receptor CD28 bind the same ligands, 
CD80 and CD86 expressed by APCs. Because CTLA-4 has a higher affinity than CD28, it 
dampens the T cell response and inhibits further T cell activation. Here is where anti-CTLA-4 
Ab ipilimumab acts and suppresses this inhibiting signal resulting in more activated T cells 249. 
CTLA-4 is exclusively expressed on T cells and regulates early T cell activation. Preclinial 
studies in mice showed that the success of anti-CTLA-4 Ab immunotherapy also stems from 
the depletion of Tregs in the tumor 
250,251. However, a recent study by Sharma et al. shows that 
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this is not true for humans as a treatment with anti-CTLA-4 does not affect FOXP3+ Tregs 
numbers in human tumors 252. 
Another inhibitory receptor on T cells is programmed cell death protein 1 (PD-1) which limits 
T cell activation in peripheral tissues. PD-1 is upregulated on T cells upon activation but can 
also be expressed by other cells, including NK cells and B cells 253. Its ligands are Programmed 
death- ligand 1 (PD-L1, B7-H1) and PD-L2 (B7-H2) which are commonly expressed on APCs, 
such as DCs and macrophages, but also on cancer cells. PD-L1 is often overexpressed in tumors 
and can be found on immune cells within the TME, such as myeloid cells 253. PD-L1 expression 
is enhanced in response to inflammatory signals including IFN-γ regulating T cell activation. 
PD-1/PD-L1 axis deals as negative feedback loop to prevent hyperactivation of T cells, 
reducing tissue damage and is crucial for maintaining peripheral tolerance 254. Thus, PD-L1 
expression by tumor cells inhibits T cell activation and suppresses their cytotoxic function by 
binding PD-1 on their surface which is blocked by PD-1 or PD-L1 targeted immunotherapy.  
TAMs can also express both PD-1 and PD-L1 and PD-1 expression in TAMs has been 
negatively correlated with their capacity to phagocytose tumor cells. Hence, anti-PD-1 Ab 
treatment also targets TAMs and it has been shown that TAM – specific PD-1 blocking 
decreases tumor growth 255. PD-L1 was also found on human TAMs in several cancer types, 
such as ovarian cancer and melanoma patients, and it positively correlates with the efficacy of 
anti-PD-1 Ab immunotherapy as monotherapy and in combination with anti-CTLA-4 Ab. 
Furthermore, PD-L1 expression on immune cells but not tumor cells is crucial for the efficacy 
of PD-L1 pathway blockade as shown in murine tumor models. Neither the knockout nor 
overexpression of PD-L1 in cancer cells affected the outcome of anti-PD-L1 directed therapy 
256 .  
The combination of anti-PD-1 and anti-CLTA-4 Abs in melanoma and non-small cell lung 
cancer showed enhanced efficacy in treating cancers compared to monotherapies 257. Therefore, 
many research groups try to find combinatorial treatments to further increase survival and 
success rates of immunotherapy.  
1.6.3 Targeting tumor-associated macrophages 
Tumor-associated myeloid cells represent the largest leukocyte population in tumors and 
TAMs became an emerging target for cancer immunotherapy during the past years. Several 
macrophage-targeted approaches are addressed to increase anti-cancer immune responses: The 
depletion of TAMs, diminishing their recruitment to the tumor site or exploiting their plasticity 
and repolarizing them from immune suppressive towards an inflammatory and tumoricidal 
phenotype.  
The depletion of TAMs can be accomplished by inhibiting their replenishment by circulating 
monocytes or by inducing apoptosis of already present ones in the tumor. Inflammatory 
monocytes are recruited to the site of tumor by CCL2-CCR2 axis; therefore, blocking of CCR2 
results in reduced TAM numbers, decreased tumor size and less metastasis 258,259 which in HCC 
has been shown to be CD8+ T cell dependent 260. Targeting the CCR2-CCL2 axis also improves 
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efficacies of immunotherapy 261 and radiotherapy 262. In pancreatic cancer patients, the 
combination of CCR2 inhibition and chemotherapy enhanced tumor shrinkage by more than 
40% compared to only chemotherapy 258. However, this approach has downsides which need 
to be considered for designing future clinical trials: The interruption of CCL2 blockade released 
monocytes into the circulation that were previously trapped in the bone marrow which in turn 
increased metastases and accelerates deaths in a murine breast cancer model 263. Another way 
of depleting TAMs is to target the CSF1-CSFR1 axis which results in apoptosis of a substantial 
part of TAMs in most tumors. Inhibition of the CSF1 and CSFR1 pathway improves the 
efficacy of immunotherapies, such as anti-PD-1 Ab and anti-CTLA-4 Ab, CD40 agonists and 
enhances T cell responses when combined with chemotherapy or radiation 264. The 
disadvantage of targeting this pathway is the depletion of other tissue-resident macrophages 
which are needed for tissue homeostasis and the removal of apoptotic cells. Also, depletion of 
TAMs leads to the loss of TAM-derived IL-15 and thus to lower numbers of NK cells in the 
tumor and increased metastasis formation. The administration of IL-15 to mice that were 
treated with CSF1R-inhibitor rescued NK cell numbers and attenuated metastasis 265. 
Recruitment of monocytes that eventually differentiate into TAMs can be modified by 
addressing the CXCR4-CXCL12 and ANG2-TIE2 axis. Treatment resistance and tumor 
regrowth after chemotherapy and radiation is connected with increased levels of CXCL12 in 
breast cancer and glioma which supports the repopulation of CXCR4-expressing TAMs 229,266. 
CXCL12 recruits mainly TIE2+ TAMs that strongly support tumor vascularization 226 and the 
inhibition of TIE2 results in reduced tumor growth, less metastases in breast cancer 267 and 
decreased angiogenesis 226. The combination of neutralizing ANG2 and blocking VEGFA by 
bispecific Abs enhances the efficacy compared to single treatments and enhances T cell 
infiltration. In response, perivascular T cells upregulate PD-L1 and the anti-tumor response of 
ANG2 and VEGFA blockade could be further increased with anti-PD-1 Ab treatment 268. 
By depleting TAMs, their tumoricidal capacity and the potential to elicit immune stimulatory 
functions as phagocytes and APCs within the tumors is also gone. Therefore, many studies 
approach to repolarize the immune suppressive and pro-tumorigenic TAMs towards a pro-
inflammatory phenotype with anti-tumor activity. One candidate is CD40, a member of the 
tumor necrosis factor (TNF) receptor super family and crucial for the co-stimulation of immune 
cells. It is expressed on APCs, as DCs, macrophages and B cells but also on other cells 
including epithelial and endothelial cells. Its ligand CD40L is predominantly expressed by 
activated CD4+ T cells. Upon binding of CD40 and CD40L, macrophages upregulate co-
stimulatory and Ag presenting molecules and release pro-inflammatory cytokines, such as IL-
12 and TNF- α. IL-12 in turn activates NK cells and enhances T cell activation. Agonistic anti- 
CD40 Abs showed reduced tumor growth and improved overall survival in pancreatic cancer 
in combination with chemotherapy and also αCD40/chemotherapy combined with αPD-1 
and/or αCTLA-4 269. Also the combination of CSF-1R antagonists and CD40 agonistic Abs 
leads to TAM polarization, increased pro-inflammatory cytokine production and CD8+ T cell 
activation and subsequently decreased tumor growth and improved survival in different mouse 
tumor models 206. 
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As the ligation of TLRs on macrophages activates them towards a pro-inflammatory 
phenotype, TLR agonists have been developed to target TAMs and TLR7, TLR8 and TLR9 
agonists show promising results by increasing macrophage repolarization and enhancing 
tumoricidal activities in breast cancer and melanoma models 210. 
Tumor cells can evade immune cell recognition by expressing specific “don`t eat me” signals 
to suppress the phagocytic capacity of macrophages. Normally, CD47 is expressed on host 
cells and upon binding to its ligand SIRP-α on macrophages it mediates a “don`t eat me” signal 
protecting the host cell against being phagocytosed. However, tumor cells can acquire CD47 
and binding of CD47 to SIRP-α results in the inhibition of TAMs. CD47 is overexpressed in 
many tumors 210 and anti-CD47 blocking Abs reduce tumor growth in several tumor models. 
Furthermore, they are currently tested in clinical trials as single agent or in combination with 
cetuximab, an inhibitor of epidermal growth factor receptor (EGFR) 206.  
Also, targeting on molecular level has been reported to successfully reprogram TAMs. The 
activation of phosphoinositide 3-kinase γ (PI3Kγ) in macrophages has been shown to skew 
TAMs to the immune suppressive phenotype and blocking PI3Kγ repolarizes TAMs including 
increases CD8+ T cell mediated anti-tumor response in PDAC 234,270. The blocking of PI3Kγ 
signaling enhances the production of pro-inflammatory genes in macrophages in a NFκB – 
dependent manner and results in tumor decrease in murine lung, pancreas, breast, melanoma 
and head and neck squamous-cell carcinoma (HNSCC) 206,234. Combining PI3Kγ inhibitors 
with anti-PD-1 Abs improved survival and further reduced tumor growth in mice with HNSCC 
234. In myeloid cells, PI3Kγ is also crucial for the recruitment to tumor sites as it is activated 
downstream of many chemoattractant receptors in mice and humans. Its activation leads to 
conformational changes in integrin alpha 4 beta 1 (VLA-4) which then binds the vascular cell 
adhesion molecule (VCAM-1) promoting extravasation of monocytes into the tumor. 
Therefore, PI3Kγ inhibition results in less myeloid cells in the tumor and reduces tumor growth 
as well as metastases in murine breast, pancreatic, lung and melanoma tumors 206. 
The targeting of TAMs by monoclonal Abs is investigated in paper II, III and IV. We target 
scavenger receptor MARCO on immune suppressive TAMs and repolarize them towards a pro-
inflammatory phenotype.  
1.6.4 Targeting natural killer cells 
NK cells are professional killers of malignant cells and they also interact with other immune 
cells to execute a potent anti-tumor response. In mice, NK cells are identified as CD3- NKp46+ 
(in BALB/c mice) or as CD3- NKp46+ NK1.1+ (in C57BL/6 mice). In humans, it is 
distinguished between immature CD3- CD56bright CD16- and mature CD3- CD56dim CD16+ NK 
cells 271,272. Immature NK cells are more susceptible to activation through cytokines IL-2, IL-
15 and IL-12 and subsequent production of IFN-γ while mature NK cells comprise more 
granules to rapidly elicit cytolytic function, containing cytolytic molecules such as granzymes 
and perforin 272. 90% of blood-circulating NK cells are of mature phenotype 273. Once NK cells 
get activated, they form immune synapses with target cells and release their preformed cytolytic 
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granules to lyse the cell. However, there are limitations for NK cells and NK cell-based 
immunotherapies based on their poor ability to infiltrate tumors and the immunosuppressive 
TME that inhibits NK cell cytolytic activity through different factors, such as TGF- β or 
adenosine. Additionally, tumor cells adapt and escape NK cell recognition by downregulating 
ligands for activating NK cell receptors or reducing MHC-I expression on their surface 271. 
NK cells can exert their cytolytic function in tumors in different ways including the release of 
cytotoxic molecules by sensing the “missing- self” HLA-1 expression, by the engagement of 
death receptors (DR) and by antibody dependent cell-mediated cytotoxicity (ADCC) – this 
broad cytotoxicity makes NK cells perfect candidates for cancer immunotherapy. 
Binding of DRs expressed by NK cells, such as Fas ligand and TRAIL, to their ligands on 
target cells will induce apoptosis through a caspase-dependent enzymatic cascade. 
Interestingly, TRAIL receptors can also be expressed by monocytes and TAMs and upon 
treatment with recombinant TRAIL these cells specifically undergo apoptosis in a caspase 8-
dependent manner 274. TRAIL-deficient mice are more susceptible to tumor growth and 
metastases and TRAIL-neutralizing Abs promote tumor progression suggesting TRAIL as an 
important player in anti-tumor responses 275. Recombinant versions of TRAIL and agonistic 
anti-TRAIL receptor Abs are currently in development 275.  
Another way of tumor cell killing by NK cells is ADCC mediated by IgG Abs binding to tumor 
cells. The Fc part is recognized by the activating Fc receptor FcγRIIIa on NK cells resulting in 
the release of cytolytic granules to kill the target cell 271. IgG1 and IgG3 Abs have the highest 
affinity for FcγRIIIa mediating tumor cell killing and clinically used Abs with increased Fc 
receptor affinity are developed at the moment. There are bi- or tri-specific killer cell engagers 
(BiKEs or TriKEs) that are against tumor-associated antigens and activating NK cells receptors 
to initiate an immunologic synapse and induce tumor cell killing more efficiently. Moreover, 
NK cell survival and activation factor IL-15 can be targeted for cancer immunotherapy and the 
administration of recombinant human IL-15 supported proliferation of NK cells and CD8+ T 
cells 276. NK cells also express inhibitory receptors that can deal as immune checkpoints 
including KIRs, T cell immunoreceptor with Ig and ITIM domains (TIGIT) and PD-1. 
Recently, it has been shown by Zhang et al. that the blocking of checkpoint receptor TIGIT 
prevents NK cell exhaustion and leads to a highly efficient NK cell-mediated tumor-specific T 
cell response 277. NK cells recruit DCs to solid tumors and activate them through IFN-γ 
production correlating with improved survival of cancer patients.  
Another promising approach is the adoptive transfer of allogeneic NK cells that have been 
activated ex vivo or chimeric antigen receptor (CAR)- modified NK cells. CARs bind tightly 
to tumor specific antigens mediating NK-tumor cell interaction and their intracellular domain 
containing ITAMs activate the NK cell. To further increase NK cell function, the intracellular 
domain can also contain co-stimulatory protein receptors 271. CAR- NK cells can be derived 
from PBMCs, NK cell lines and hematopoietic stem cells which makes them more attractive 
then CAR- T cell therapy because these are required to be autologous.  
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2 THE PRESENT STUDY 
2.1 AIMS 
This thesis aims to investigate the role of scavenger receptor MARCO in immune responses 
as well as its potential as target for cancer immunotherapy.  
Paper I – To study the effect of targeting scavenger receptor MARCO on marginal zone 
macrophages by monoclonal antibodies and the subsequent immune response. 
Paper II – To examine the impact of targeting scavenger receptor MARCO on tumor-
associated macrophages by monoclonal antibodies and modulating the immune suppressive 
tumor microenvironment. 
Paper III – To investigate the mechanism of how anti-MARCO antibody treatment leads to 
decreased tumor burden in melanoma.  
Paper IV - To modulate human immune suppressive MARCO+ myeloid cells to enhance the 
tumorigenic phenotype of immune cells in pancreatic cancer by engaging MARCO. 
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2.2 RESULTS AND DISCUSSION 
2.2.1 Marginal zone macrophages regulate antigen transport by B cells to 
the follicle in the spleen via CD21 (Paper I) 
MARCO expressing MZMs aligning the marginal sinus in the spleen are positioned 
strategically to filter antigens and pathogens from the circulation. It has previously been shown 
that SLE patients have autoantibodies against scavenger receptor MARCO but their role in the 
disease and impact on other immune cells is not known 44. Therefore, in this study we address 
the impact of anti-MARCO Abs on MZMs and the interaction between MZMs and the closely 
located MZBs as well as on the subsequent immune response towards foreign Ag.  
To investigate the impact of anti-MARCO Ab on the MZM/MZB interaction, we injected rat 
anti-mouse MARCO Abs intravenously (i.v.) in wildtype (wt) mice. We confirmed that we 
specifically targeted MARCO+ MZMs without depleting them and this resulted in the gradual 
loss of complement receptor 2 (CD21) on MZBs. Already 1 hour after Ab injection we noticed 
a reduction of CD21 on MZBs; other B cell populations were also affected but to a lesser 
degree. Further analysis excluded local complement activation or receptor internalization to be 
responsible for the reduction in CD21. Next, we investigated whether the alternative splice – 
variant CD35 (complement receptor 1) was affected and monitored that it was also reduced on 
MZBs to the same extent as CD21; however, leaving the CD35 expression on FDCs unaffected. 
Polyclonal Ab serum from mice immunized with MARCO protein also led to the reduction of 
CD21 on MZBs ruling out any inter-species effect. Moreover, as MARCO can also be 
upregulated on macrophages upon binding of bacterial Ag, such as LPS, we analyzed  
MyD88-, TLR2-, TLR4- and TLR9- deficient mice and found none of the molecules were 
involved in mediating the reduction in CD21 on MZBs after anti-MARCO Ab administration. 
Also, we excluded any assistance of FcγRs. 
The fact that CD21 on MZBs is so quickly reduced after anti- MARCO Ab injection led us to 
the hypothesis that CD21 might be cleaved upon MARCO engagement. It is known that CD21 
and adhesion molecule L-selectin CD62L can be shedded from B cells 278. Indeed, we found a 
similar decrease of CD62L on MZBs after MARCO engagement as CD21. Purinergic 
receptors, such as P2X7R, are known to cleave CD21 and CD62L in response to extracellular 
ATP and soluble CD21 has been found 
linked to different inflammatory 
responses and autoimmune diseases 278. 
Therefore, we set up in vitro experiments 
to analyze the mechanism underlying the 
decrease in CD21, CD35 and CD62L on 
MZBs after anti-MARCO Ab injection. 
Using MARCO+ peritoneal 
macrophages, we detected the release of 
extracellular ATP already 5 minutes 
after Ab stimulation (Figure 6). We 
Figure 6: The release of extracellular ATP after anti-
MARCO Ab treatment. Peritoneal macrophages were 
stimulated and analyzed in vitro. 
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confirmed that the loss of CD21 and CD62L on the surface of MZBs is dependent on 
extracellular ATP using cultures of splenocytes in vitro. Co-culture experiments of MARCO+ 
macrophages and splenocytes revealed that the anti-MARCO Ab mediated CD21 decrease 
could be reversed by adding ATPase. Together, this strengthened our hypothesis that 
macrophages mediated ATP release is connected to the loss of CD21. To confirm this in vivo, 
we injected ATP i.v. which mimicked the reduction of CD62L on MZBs that we saw in vitro 
but not CD21. This could be because of differences in receptor expression or cleavage efficacy 
in vivo. To further delineate the involvement of extracellular ATP we analyzed the expression 
of ectoenzyme CD39 which is an important player in the conversion from extracellular ATP to 
adenosine which in turn is known for its immune modulatory and immune suppressive 
capacities 279. Interestingly, ectonucleotidase CD39 was upregulated on macrophages upon 24 
hours of anti-MARCO Ab stimulation in vitro to similar extent as after the addition of 
extracellular ATP. Normally, extracellular ATP acts as a danger signal and can program 
macrophages towards a pro-inflammatory phenotype 170 as well as activate other immune cells. 
Thus, it is important to have modulatory mechanisms to prevent over activation by upregulating 
molecules, such as ectonucleotidases. These enzymes convert ATP to AMP and to the 
immunomodulatory adenosine which in turn suppresses immune cells 279. To further explore 
the involvement of the purinergic receptor P2X7R, we injected P2X7R- deficient mice with 
anti-MARCO Ab or vehicle i.v. in vivo or added ATP to the cultures of P2X7R- deficient 
splenocytes and we still saw a reduction of CD21 and CD62L suggesting that other ATP-driven 
mechanisms must be responsible for the loss of these receptors.  
Next, we investigated whether any functions of MZBs are impaired by the CD21 loss as MZBs 
are important players for a potent immune response. In the spleen, MZBs migrate between 
marginal zone and follicle to transport antigen and deliver it to FDCs. Targeting MARCO on 
MZMs did not interfere with the shuttling of MZBs to the follicle but it reduced the transport 
of CD21- dependent Ag to the follicle resulting in less Ag deposition on FDCs after 24 hours. 
Scavenger receptor MARCO is known to bind self-Ags and the mechanism we discovered 
could be a modulatory mechanism to prevent the transport of these self-Ags to the follicle 
inducing an autoimmune response. The deposition of Ag on FDCs is important for the 
activation of germinal center formation and the subsequent immune response. Thus, we 
investigated the humoral response and found less GC B cells as well as reduced IgM, IgG1, 
IgG3 titers in response to a T cell – dependent Ag and less IgM to T cell – independent Ag. 
Considering the decreased Ag transport and lower Ab levels upon anti-MARCO Ab injection, 
it is possible that the anti-MARCO autoantibodies found in SLE patients are one factor for the 
increased risk for inflammation in these patients.  
Taken together, this study reveals a new mechanism of how MZMs in the spleen can regulate 
the adaptive and humoral immune response. Anti-MARCO Ab injection leads to the release of 
extracellular ATP by MARCO expressing macrophages which in turn results in the loss of 
CD21 and CD62L on MZBs. Moreover, CD21- dependent Ag transport by MZBs into the 
follicle and Ag deposition on FDCs is reduced after anti-MARCO Ab injection and the 
subsequent humoral response is impaired. Our findings go in line with that SLE patients also 
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show lower levels of CD21 on B cells and it will be interesting to investigate this further to 
find out if it is possible to target that pathway to modulate Ag transportation into the follicle to 
prevent unwanted immune responses. 
2.2.2 Reprogramming tumor-associated macrophages by antibody targeting 
inhibits cancer progression and metastasis (Paper II) 
Tumors are diverse tissues that consist of many different cell types besides malignant cells. 
Immune cells play an important role in the TME and inflammation has been identified as one 
of the hallmarks of cancer 181. Especially tumor-associated macrophages (TAMs) as a very 
plastic cell type can contribute to tumor growth in different ways: They can enhance tumor 
progression by supporting angiogenesis, metastasis formation or the suppression of other 
immune cells; however, they can also show inflammatory properties by the release of 
extracellular ATP activating other effector cells or the expression of pro-inflammatory 
cytokines. TAMs are present in nearly all tumors and they are known to play a role in 
maintaining an immune suppressive TME 206.  
So far, the expression of scavenger receptor MARCO has been thought to be restricted to some 
macrophage subpopulations, such as alveolar, peritoneal or marginal zone macrophages that 
we targeted in paper I. However, we found MARCO also expressed on TAMs in several mouse 
tumor models, including melanoma, mammary adenocarcinoma and colon adenocarcinoma. 
We identified MARCO to be exclusively co-localized with the macrophage marker F4/80 and 
not expressed on other immune cells. However, not all F4/80+ cells were positive for MARCO: 
By sorting different TAM subpopulations we detected CD45+ CD11b+ Ly6G- Ly6Clow 
MHCIIlow cells as the MARCO expressing macrophages. MARCO expression correlated with 
high expression of typical genes that are expressed by anti-inflammatory macrophages, such 
as arg1, fizz1 and low expression of genes that relate to inflammation such as Tnf, Il-1b or 
Nos2. This suggested that MARCO is a marker for an anti-inflammatory and immune 
suppressive TAM subset. To further investigate the MARCO+ subpopulation and what drives 
MARCO expression, we set up an in vitro system using bone marrow-derived macrophages 
(BMDMs) which we polarized towards the pro-inflammatory (IFN-γ + LPS) or immune 
suppressive (IL-4 + IL-13) phenotype as well as incubated with B16 melanoma cell line-
conditioned medium. Our findings in vitro go in line with the in vivo data and we confirmed 
that MARCO is expressed on the immune suppressive subtype and can be induced by tumor-
conditioned medium. As the cytokines IL-10 and TGF-β are prominent immune suppressive 
cytokines in the TME and they can polarize TAMs towards an anti-inflammatory phenotype, 
we evaluated if they also have the capacity to induce MARCO expression and both cytokines 
certainly upregulated MARCO in vitro on a peritoneal macrophage cell line.  
Previously, we have shown that targeting MARCO with monoclonal Abs influences the 
immune response by modulating Ag shuttling and Ab production (paper I), thus, we analysed 
if targeting MARCO+ TAMs also changes the anti-tumor immune responses. For this, we 
injected a rat anti-mouse MARCO Ab i.v. and monitored tumor growth in the B16 melanoma 
and 4T1 breast adenocarcinoma model. We confirmed that the anti-MARCO Ab infiltrated the 
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tumor and reached the MARCO expressing 
cells. Interestingly, anti-MARCO Ab 
treatment led to decreased tumor growth in 
both tumor models and in the 4T1 mammary 
carcinoma also to less metastasis formation to 
the lungs (Figure 7). Furthermore, we noticed 
an increase in pro-inflammatory and a 
decrease in immune suppressive TAMs in the 
4T1 model as well as an altered CD4+/CD8+ T 
cell ratio, less regulatory T cells within the 
tumor and more GC B cells in the draining 
lymph node of tumor-bearing mice.  
To further investigate the properties of anti-
MARCO Ab treatment as anti-cancer 
immunotherapy, we used the B16 melanoma 
model. Tumor cells were injected 
subcutaneously and tumor growth was 
inhibited by anti-MARCO Ab treatment to the same extent as with the TA99 Ab which is 
known to induce ADCC to B16 tumor cells. By sorting bulk TAMs and analysing their gene 
expression, we observed increased expression of pro-inflammatory genes in the anti-MARCO 
Ab treated mice compared to the control group, such as Il1β. Moreover, TAMs from the treated 
group also showed a decrease in anti-inflammatory genes, such as il10, suggesting the 
reprogramming from immune suppressive to a pro-inflammatory macrophage subtype 
mediated by anti-MARCO Ab administration. Analysis by flow cytometry revealed that the 
ratio of intratumoral CD4+/CD8+ T cells was altered, numbers of Tregs decreased and OVA – 
specific CD8+ T cells were increased. This goes in line with increased OVA- specific IgG2b 
levels in the serum of anti-MARCO Ab treated mice.  
Harnessing the potential of the immune system is already implemented and immune checkpoint 
inhibitors targeting T cells show promising results in patients of several cancer types. However, 
these immunotherapies still have limitations and do not work for all patients. Therefore, we 
assessed the capacity of combining the anti – MARCO Ab treatment with the checkpoint 
inhibitor anti-CTLA-4. Interestingly, the combination of these two mAb treatments increased 
their efficacy compared to single treatments resulting in less tumor growth in the B16 
melanoma as well as the MC38 colon adenocarcinoma model. 
It has been shown that anti-tumor Abs require the engagement of FcR to be functional either 
through promoting cytotoxicity or through crosslinking of the receptors and thus inducing 
agonistic capacity 238. Therefore, we evaluated the involvement of FcR in the anti-MARCO Ab 
mediated anti-tumor effect. For this, we generated anti-MARCO Ab variants with modified Fc 
domains or used mice that were either deficient for all FcR, only the activating FcγRI, III or IV 
or only missing the inhibitory FcγRIIb. Consequently, we observed that the therapeutic anti-
Figure 7: Targeting MARCO by anti-MARCO Ab 
reduces tumor growth in vivo. Tumor volume in B16 
melanoma (day 12, left) and 4T1 mammary carcinoma 
(day 21, right) tumor models in control and anti-
MARCO Ab treated mice. Mice were inoculated with 
tumor cells subcutaneously and treated with anti-
MARCO Ab intravenously.   
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tumor effect mediated by anti-MARCO Ab was dependent on the inhibitory FcγRIIb which we 
also found to be highly expressed on MARCO+ TAMs in vivo and on in vitro derived MARCO+ 
TAMs.  
Additionally, to translate our findings to humans we next investigated MARCO expression in 
human breast cancer and metastatic melanoma biopsies. We had access to the The Cancer 
Genome Atlas (TCGA) and KI/Clinseq databases and observed the highest MARCO 
expression in the basal (triple negative) subgroup of breast cancer patients and for melanoma 
patients in distal metastases. Taken together, in both tumor types MARCO expression 
correlates with the more aggressive and metastatic cancer subtypes. In support with our 
findings in mice, MARCO expression was also in humans associated with immune suppressive 
macrophage markers such as il4r, retnlb and cd163 and FcγRIIb and furthermore, with an EMT 
gene signature expressing the known EMT regulators mmp9, snai1 and twist1 indicating a 
metastasis-promoting role.  
Finally, we validated MARCO expression on human tumor sections from breast cancer and 
melanoma patients by immunofluorescence and confirmed that MARCO is co-expressed with 
macrophage marker CD68+ and that it also strongly correlates with CD206 and CD163 which 
are both markers for immune suppressive macrophages in humans. Furthermore, triple negative 
breast cancer patients had the highest infiltration of CD68+ TAMs. These findings strengthen 
our hypothesis of MARCO being a marker for the immune suppressive macrophage 
subpopulation also in humans.  
In summary, this study uncovered scavenger receptor MARCO as a marker for the immune 
suppressive TAM population and revealed it as novel candidate for targeted immunotherapy 
using Abs. MARCO is also expressed in clinical samples of human breast cancer and 
melanoma patients where it correlates with anti-inflammatory and metastatic genes. Targeting 
MARCO with mAbs in pre-clinical mouse models 
showed impressive decrease of tumor growth in 
primary as well as metastatic tumors in several 
cancer models. This is due to re-programming of 
immune suppressive macrophages towards a pro-
inflammatory phenotype with increased anti- tumor 
immunogenicity (Figure 8). The combinatorial 
treatment of anti-MARCO Ab and checkpoint 
inhibitor anti-CTLA-4 Abs resulted in further 
decrease in tumor size compared to single 
treatments. Altogether, these data suggest that 
TAMs can be targeted with Abs to modulate the 
immune suppressive TME by activating immune 
cells to increase their immunogenicity. 
Figure 8: Reprogramming of immune 
suppressive to pro-inflammatory TAMs by 
targeting MARCO with antibodies.  
From reference #80. 
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2.2.3 Targeting scavenger receptor MARCO on tumor-associated 
macrophages activates TRAIL-dependent tumor cell killing by NK cells 
in melanoma (Paper III) 
Immunotherapy is a promising approach for anti-cancer therapy and with checkpoint inhibitors 
anti-CTLA-4, anti-PD-1 and anti-PD-L1 Abs there are already some successfully used in the 
clinics. Most of the FDA-approved immunotherapies target T cells but as we have shown 
recently, also TAMs can be targeted by Abs (paper II). Thus, we re-program immune 
suppressive and tumor-supporting macrophages towards a pro-inflammatory phenotype with 
tumoricidal capacities. Based on this, we wanted to understand the impact of anti-MARCO Ab 
treatment on the TME and how it results in reduced tumor growth. 
In order to elucidate the mechanism of anti-MARCO Ab treatment resulting in smaller tumors, 
we investigated the MARCO+ TAMs in more detail. Interestingly, in the B16 melanoma model 
they showed a perivascular macrophage phenotype with high expression of Tie2 and CXCR4 
229,280 and were in close proximity to CD31+ blood vessels. Performing whole tumor imaging, 
we revealed that anti-MARCO Ab treatment decreased the tortuosity of CD31+ vessels with a 
trend to reduced numbers of nodes but vessel radius and volume were not affected. This 
suggests that targeting MARCO does not have a profound effect on tumor vascularization but 
affects it partly thus leading to tumor reduction. 
Further investigating the events mediated by MARCO engagement, we found scavenger 
receptor MARCO to be internalized upon Ab binding which gradually increases with time and 
is partly dependent on FcR. It is still not known how MARCO exactly signals but it has been 
shown that class A scavenger receptors are internalized upon ligand binding 147 which strongly 
suggest that MARCO has a similar signaling pathway.  
We have previously shown that targeting MARCO induced the release of extracellular ATP by 
macrophages (paper I); therefore, we evaluated whether the anti-MARCO Ab mediated anti-
tumor effect is dependent on the ATP-sensing receptor P2X7R. P2X7R is an ionotropic 
receptor that forms pores upon ligand (ATP) binding. The binding of ATP leads to 
conformational rearrangements allowing transmembrane fluxes needed for the activation by 
P2X7R 16. Running the B16 melanoma model in P2X7R–deficient mice validated that this 
receptor is indeed needed for the anti-tumor response by MARCO targeted therapy. P2X7R 
can activate the NLRP3 inflammasome and thus lead to a pro-inflammatory phenotype; 
however, tumor studies in NLRP3-deficient mice elucidated that anti-MARCO Ab treatment 
does not require NLRP3 to reveal its tumorigenic properties. Another way of action would be 
that P2X7R results in metabolic changes within the cells. And indeed, after anti-MARCO Ab 
treatment, we detected that MARCO+ macrophages changed their metabolomics including 
increased glycolysis and Hif1α expression in vitro. Augmented glycolysis and HIF-1α levels 
are known to be associated with pro-inflammatory macrophage phenotype 121,281 which further 
supports our findings from paper I and II.  
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To assess the role of other immune cells in the anti-tumor effect mediated by anti-MARCO Ab 
treatment, we depleted different effector cells in the B16 melanoma model, in particular CD4+ 
or CD8+ T cells or NK cells. We injected depleting Abs 24 hours before tumor cell inoculation 
and administered the anti-MARCO Ab every third day. Surprisingly, the anti-MARCO Ab 
immunotherapy in the melanoma model was completely independent on T cells but dependent 
on NK cells (Figure 9).  
Also, immunofluorescence stainings of tumor sections verified MARCO+ cells closely located 
to NK cells. However, we could not detect any differences in the expression of NK cell 
maturation or activation markers after anti-MARCO Ab treatment, as NKG2D, DNAM1, 
KLRG1 expression measured by flow cytometry. Interestingly, we discovered a decrease of 
ectoenzyme CD39 on NK cells after the Ab injection. As described before, CD39 is involved 
in the conversion from extracellular ATP to AMP which is then further converted to adenosine 
by CD73 279. Adenosine has immune suppressive capacities and reduces NK cell cytotoxicity, 
so the decrease of CD39 might be a way to regulate the levels of immune suppressive adenosine 
in the area and to keep the NK cells more activated. This strengthens our hypothesis that 
targeting MARCO by Ab creates a more immunogenic TME. Additionally, we detected higher 
levels of IL-15 in the serum of tumor-bearing anti-MARCO Ab treated mice which is known 
to activate NK cells. As our anti-tumor effect is Ab-mediated, we ruled out that NK cells 
deplete MARCO+ immune suppressive TAMs by ADCC using FcγRIII-deficient mice. We 
found increased levels of the effector molecules perforin and TRAIL on intra-tumoral NK cells 
after anti-MARCO Ab treatment and confirmed that our B16 melanoma cell line expresses the 
TRAIL ligand DR5. By blocking TRAIL in vivo, we observed that the MARCO-directed 
immunotherapy needed the TRAIL-dependent killing mechanism to work but not perforin as 
tumor experiments in perforin-deficient mice demonstrated. 
Additionally, the effect of MARCO targeting immunotherapy in combination with the immune 
checkpoint inhibitors anti-PD-1 and anti-PD-L1 Abs has been evaluated. These checkpoint 
Figure 9: Anti-tumor effect mediated by anti-MARCO Ab treatment is dependent on NK cells in the B16 
melanoma model. Tumor volume is shown on day 10 and in WT mice we see smaller tumors in the treated group 
(empty dots) compared to PBS control group (black dots). However, when NK cells were depleted this decrease 
in tumor size upon anti-MARCO treatment (blue dots) is gone compared to PBS group (green dots). Mice were 
injected with NK cell depleting Abs or vehicle 24 hours before subcutaneous tumor cell inoculation and then 
treated with anti-MARCO Ab every third day. 
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therapies are promising and show impressive results in the clinics; however, not all patients are 
responding to single therapies which is why many studies try to find combinatorial treatments. 
With anti-PD-1 and anti-PD-L1 Ab mainly targeting T cells and anti-MARCO Ab directed at 
TAMs, we combined these immunotherapies. The combination of anti-MARCO Ab with either 
one of the checkpoint inhibitors increased their efficacy compared to single treatments. 
Furthermore, we detected increased NK cell infiltration of the tumor but no dramatic 
differences in other immune cells. 
To translate our findings and the connection between anti-MARCO Ab treatment and NK cells 
to humans, we set up an in vitro system to establish human MARCO expressing macrophages 
from CD14+ monocytes. We used IFN-γ + LPS for pro-inflammatory macrophages, IL4 + IL-
10 for immune suppressive macrophages and in addition, conditioned medium from three 
different human primary melanoma cell lines (ANRU, KADA and MAT02) to polarize the 
macrophages. We previously showed that MARCO is expressed on immune suppressive 
TAMs in several human cancers including melanoma patients (paper II) and as expected 
MARCO expression was induced by IL-4 + IL-10 and the melanoma cell-conditioned media.  
To address the human MARCO receptor, we produced anti-human MARCO Ab by 
immunizing mouse MARCO-deficient mice with the human MARCO protein. We then 
performed co-culture experiments of human NK cells and macrophages in tumor-conditioned 
medium which blocked NK cell activation compared to normal medium, measured by IFN-γ 
production, proliferation measured by Ki67 and degranulation analyzed by CD107a in vitro. 
However, when macrophages were pre-treated with anti-hMARCO Ab we were able to re-
active the NK cells by restoring activation, proliferation and degranulation capacity. 
Finally, we assessed the impact of anti-hMARCO Ab treatment on the killing capacity of NK 
cells towards the primary human melanoma tumor cell lines KADA and ANRU. For this, NK 
cells were co-cultured with macrophages in tumor–conditioned medium which decreased the 
killing ability by NK cells compared to normal medium. However, when adding anti-
hMARCO Ab to the cultures, we rescued NK cell activation resulting in enhanced killing.  
Overall, our results show for the first time that targeting immune suppressive TAMs by mAbs 
leads not only to re-programming of TAMs towards a pro-inflammatory and more tumorigenic 
phenotype but that MARCO directed immunotherapy also activates NK cells for increased 
TRAIL-mediated tumor cell killing. This mechanism also holds in in vitro assays with human 
cells which is promising for the future to bring anti-MARCO Abs into the clinics. Current 
immunotherapies mostly target and activate T cells but it is important to identify combinatorial 
treatments to not only target one single cell type to enhance the success rates of anti-cancer 
therapies. We show that targeting MARCO works well together with currently used 
immunotherapies anti-PD-1 and anti-PD-L1 Ab resulting in further reduction of tumor sizes. 
Altogether, this study suggests MARCO directed immunotherapy as new promising 
immunotherapeutic approach for cancer immunotherapy activating two different immune cells 
simultaneously to enhance their anti-tumor properties.  
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2.2.4 Antibody targeting of tumor associated macrophages in pancreatic 
cancer remodels the tumor microenvironment and revives immune 
targeting of tumor cells (paper IV) 
Pancreatic cancer is one of the leading causes of death worldwide with very poor prognosis 
and is still considered largely incurable. Patients get diagnosed too late and the cancer has 
mostly already progressed to the point where surgical removal is impossible. Conventional 
anti-cancer therapies do not work and the immune checkpoint inhibitors anti-PD-1 and anti-
CTLA-4 did not show the hoped success. The most common type of pancreatic cancer is 
pancreatic ductal adenocarcinoma (PDAC; 95% of all cases) where the tumor tissue consists 
of very dense fibrotic connective tissue. This makes it difficult to deliver drugs into the tumor 
and low T cell infiltration defines it as “cold” tumor which impedes immunotherapy as well. 
As shown in paper II and III, we detected MARCO+ TAMs not only in murine tumors but also 
in human cancers, such as melanoma and breast cancer patients and it has also been found in 
human lung cancer 179. Thus, we evaluated MARCO expression also in human pancreatic 
cancer patients using TCGA database. Interestingly, MARCO was higher expressed in PDAC 
patients compared to healthy individuals and correlated with less survival. 
Immunofluorescence analysis confirmed MARCO to be expressed on CD68+ macrophages and 
we hypothesized that we can also target MARCO+ TAMs in human pancreatic cancer patients. 
To study scavenger receptor MARCO in humans in more detail we set up an in vitro system. 
First, we differentiated CD14+ myeloid cells with M-CSF to macrophages before we polarized 
them with different cytokine cocktails to uncover what drives the highest MARCO expression. 
We used the known stimuli for pro-inflammatory macrophages (IFN-γ + LPS) and anti-
inflammatory macrophages (IL-4 + IL-10) as well as combinations of other immune 
suppressive cytokines that are known to be present in TME, such as IL-13 and TGF- β. IL-10 
alone induced MARCO and CD163 expression, but not CD206 which is a marker for functional 
immune suppressive macrophages in humans. As the combination of IL-4 + IL-10 induced 
MARCO, CD163 and CD206 expression, we continued with this cytokine stimulation mix for 
further experiments. So far not much is known about MARCO+ cells in humans and we found 
that MARCO correlates with an immune regulatory and tissue remodeling macrophage type in 
humans with similar gene expression signature as mice, such as increased levels of il10 and 
fizz1. This verifies our hypothesis that MARCO is a marker for immune suppressive 
macrophage subtype also in humans. 
To evaluate the role of MARCO in human pancreatic tumors, we co-cultured naïve 
macrophages with different pancreatic cancer cell lines and analyzed phenotype and function 
of the macrophages. The co-cultures were performed in trans well plates to only allow soluble 
factors to pass through the trans well inserts. Interestingly, all pancreatic cancer cell lines 
induced MARCO and CD163 expression but not CD206 - the same phenotype that we 
observed with only IL-10 stimulation in the previous experiment. Thus, we confirmed the 
presence of IL-10 in the tumor-conditioned medium which levels were correlating with 
MARCO expression and neutralizing IL-10 reduced MARCO expression. IL-10 is a known 
negative modulator of inflammatory responses in macrophages through STAT3 and indeed, 
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inhibiting STAT3 resulted in decreased MARCO expression suggesting STAT3 is required to 
induce MARCO.  
All tumors comprise of necrotic and hypoxic areas. As hypoxia can cause macrophage 
polarization towards the immune suppressive phenotype 282, we wanted to investigate the effect 
of hypoxia on MARCO expression. For this, myeloid cells were co-cultured in trans wells with 
the human pancreatic cancer cell line that induced the highest MARCO expression under 
hypoxic or normoxic conditions. Surprisingly, cells that were cultured under hypoxic 
conditions showed a phenotype that has been described for MDSCs, including high expression 
of Arginase-1, less HLADR but no change in VEGF or CD206. These cells were also positive 
for MARCO and CD163. To elucidate this phenotype, we polarized myeloid cells into MDSCs 
using the known stimulation mix (GM-CSF + IL-6) which showed exactly the same phenotype 
as the MARCO+ cells under hypoxic conditions. Thus, we concluded that hypoxia drives 
MARCO expression also on other immune suppressive myeloid cells not only macrophages. 
TAMs and MDSCs are known as the most potent immune suppressive cells in the TME, why 
we next assessed the ability of MARCO+ myeloid cells to suppress cytotoxic T cell and NK 
cell function. For this, pro- or anti-inflammatory macrophages or MDSCs were co-cultured 
with T cells or NK cells and the latter were analyzed for activation (measured by IFN-γ 
production) and proliferation (measured by Ki67 expression). Interestingly, all MARCO+ 
myeloid cells inhibited T cell and NK cell activity whereas TAMs were slightly stronger 
suppressors than MDSCs. Also, myeloid cells that were co-cultured with pancreatic cancer cell 
lines in a trans well system before being co-cultured with T cells or NK cells were sufficient in 
suppressing the activation and proliferation of T cells and NK cells. This suggests that all 
MARCO+ myeloid cells are able to suppress cytotoxic effector cells no matter if MARCO 
expression is cytokine- or tumor cell- induced.  
We previously showed that targeting MARCO by Ab can reprogram immune suppressive 
TAMs to a pro-inflammatory phenotype revealing MARCO as potential target for cancer 
immunotherapy (paper II). Thus, we produced anti-human MARCO Ab that has also been 
described in paper III by immunizing MARCO-deficient mice with human MARCO 
(hMARCO) protein. These antibody clones were tested for endotoxin contamination and two 
revealed high levels including the commercially available antibody. As the Fc domain is 
important for the effector functions of therapeutic antibodies 283 we tested the isotypes of our 
clones and identified them all as IgG1.  
To assess the impact of anti- hMARCO treatment on other immune cells, we co-cultured anti-
hMARCO Ab or vehicle pre-retreated pro- or anti-inflammatory macrophages with T cells or 
NK cells. As expected, anti-inflammatory macrophages suppressed T cell and NK cells 
activation and proliferation dramatically but adding anti-hMARCO Ab to the cultures reversed 
this impressively. Moreover, the killing capacity of K562 and different pancreatic cancer cell 
lines by T and NK cells was augmented drastically when they were co-cultured with anti-
hMARCO Ab pre-treated macrophages. 
 44 
The release of extracellular ATP counts as danger signal and leads to macrophage polarization 
and a more immunogenic TME 170,284. We have shown in paper I that engaging MARCO by 
Abs results in the release of extracellular ATP in murine MARCO+ macrophages in vitro. 
Based on this, we examined if targeting the human receptor shows the same effect and in fact, 
we observed that targeting hMARCO with our in-house produced Abs also resulted in ATP 
release by primary macrophages. For further analysis, we continued with one Ab clone that 
resulted in the highest ATP release and had the lowest endotoxin levels. ATP is a key activator 
of the NLRP3 and this in turns leads to the release of IL-18 15. Therefore, we next investigated 
the involvement of NLRP3 inflammasome and the release of IL-18 after Ab incubation. In co-
cultures of anti-hMARCO Ab pre-treated macrophages with T cells or NK cells, we indeed 
observed that inhibiting or neutralizing NLRP3 and IL-18 prevented the anti-hMARCO Ab 
mediated effect to re-activate T or NK cells (measured by IFN-γ production) suggesting that 
the NLRP3 inflammasome is required downstream for functional signaling of hMARCO in 
contrast to mice where NLRP3-deficient mice did not reveal any involvement for the anti-
tumor effect. Further, we validated that anti-hMARCO Ab also reprograms human immune 
suppressive MARCO+ myeloid cells to an inflammatory phenotype with increased expression 
of pro-inflammatory genes, such as Tnfα and Il1β, and the reduction in anti-inflammatory 
genes, such as Mrc1 and Il10, which goes in line with our findings in mice. 
As described above, STAT3 was identified to positively regulate MARCO expression on 
myeloid cells. Therefore, we inhibited STAT3 in macrophages prior co-culture with T and NK 
cells and surprisingly, inhibition of STAT3 re-activated IFN-γ expression in T and NK cells to 
the same extent as anti-hMARCO Ab did.  
Finally, we determined the location of MARCO+ cells in human pancreatic tumor sections in 
relation to T cells and NK cells. Interestingly, MARCO+ cells were infiltrating the tumors 
whereas T cells and NK cells were predominantly found outside the tumor separated from 
MARCO+ cells and confirming the poor infiltrating of lymphocytes into “cold” tumors 285. 
Increased numbers of T cells and NK cells correlated negatively with MARCO+ cells.  
Overall, the data show that MARCO+ myeloid cells are present in human pancreatic cancers. 
MARCO is found on human immune suppressive TAMs but also on MDSC-like cells and its 
expression can be induced by pancreatic cancer cell lines. We can target hMARCO with our 
in-house produced anti-hMARCO Ab and reprogram human suppressive myeloid cells to 
restore cytotoxic anti-tumor function of human T cells and NK cells. Therefore, hMARCO- 
directed immunotherapy is a very promising approach in treating pancreatic cancer patients. 
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2.3 CONCLUSIONS AND FUTURE PERSPECTIVES 
A dysregulated immune system is the reason for many diseases, such as autoimmune diseases, 
and can support the development of others, such as cancer. It is challenging to obtain the perfect 
balance between pro- and anti-inflammatory responses and immunotherapy became an 
established approach of treating cancer to release the brakes of the immune system. Immune 
checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 Abs, are already used in the clinics 
and show impressive results improving survival of cancer patients and reducing primary tumor 
growth as well as metastases formation. However, not all patients respond to current immune 
checkpoint inhibitors or other anti-cancer therapies including chemotherapy. Therefore, it is 
crucial to find novel targets for cancer immunotherapy to further improve its efficacy, possibly 
in combination with other anti-cancer therapies. As TAMs represent an abundant population in 
most of the tumors and promote tumor growth in several ways, the focus of this thesis has been 
to uncover the role of scavenger receptor MARCO in mediating immune responses and in 
particular, its potential as immunotherapeutic target and the impact of targeting MARCO by 
monoclonal Abs on tumor growth and the TME. 
The main findings of this thesis are the following: 
I. Targeting scavenger receptor MARCO on marginal zone macrophages in the 
spleen reduces antigen transport by marginal zone B cells and modulates the 
subsequent immune response 
Paper I reveals a novel mechanism of how the interaction between MZMs and MZBs in the 
spleen can be modulated by targeting scavenger receptor MARCO on MZMs. Engagement of 
MARCO by monoclonal Abs reduces the expression of CD21 and CD62L on MZBs and 
impairs Ag shuttling and subsequent humoral immune responses. Moreover, targeting 
MARCO by Abs leads to the release of extracellular ATP by macrophages. ATP signals 
through purinergic receptors, such as P2X7, and is known to activate immune cells, inducing 
inflammasome assembly and the expression of IL-1β and IL-18 16. Also, extracellular ATP 
levels polarize macrophages towards a pro-inflammatory M1 subtype with anti-tumoral 
properties 170 which is why increased levels are good in the TME to initiate immune responses. 
Simultaneously, we see an increase in CD39 on MZMs upon anti-MARCO Ab injection. The 
ectoenzyme CD39 is involved in the conversion from ATP to adenosine which in turn has 
immune suppressive functions. This most probably deals as modulatory mechanism to prevent 
hyperactivation of these cells. Adenosine can inhibit the activation of many immune cells 
including effector cells such as NK cells. Thus, paper I identifies a scavenger receptor with 
immunomodulatory properties as possible immunotherapeutic target for further approaches. 
Further experiments need to be performed uncovering the signaling mechanism of MARCO 
on intracellular level as well as if targeting MARCO also modulates other components of the 
immune system. 
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II. MARCO is a marker for immune suppressive tumor-associated macrophages and 
targeting by antibodies re-polarizes the macrophages and reduces tumor growth 
In paper II, we identify scavenger receptor MARCO as a marker for the immune suppressive 
TAM subtype and discover MARCO as a novel target for Ab directed anti-cancer 
immunotherapy by which we can re-program pro-tumorigenic macrophages towards a pro-
inflammatory and tumoricidal phenotype. We verified the success of anti-MARCO Ab 
mediated anti-cancer effect in three different mouse models and confirmed the expression of 
MARCO on clinical patient samples of human breast cancer and melanoma patients. The first 
macrophage- targeted therapies aimed to deplete TAMs completely; however, depleting TAMs 
by using anti-CSF1 Ab is not the right way to proceed as this removes macrophages from the 
whole system. They are important sentinels and needed for maintaining the homeostasis and 
clearing apoptotic cells. Thus, it is definitively better to re-program immune suppressive TAMs 
to tumoricidal macrophages. For the future it will be important to expand the studies to other 
cancer types and see if MARCO can even work as a biomarker for some cancers. Furthermore, 
because MARCO expression is correlated with the most aggressive and metastatic cancer types 
in humans it is important to translate our findings to see if anti-MARCO Ab therapy also works 
in humans. In paper I we have shown that targeting MARCO by monoclonal Abs leads to the 
release of extracellular ATP which is known to polarize macrophages towards a pro-
inflammatory phenotype 170. This goes in line with our findings in paper II, that after anti-
MARCO Ab treatment immune suppressive TAMs shift towards a pro-inflammatory 
phenotype on gene expression and protein level analyzed by flow cytometry. Further studies 
addressing the exact mechanism of action of scavenger receptor MARCO need to be performed 
to fully understand how engaging MARCO by Ab leads to reduced tumor growth. More 
insights are needed to design clinically relevant combinatorial treatments and to reach 
maximum treatment success.  
III. MARCO engagement on tumor-associated macrophages by antibodies recruits and 
activates NK cells to increase their TRAIL-dependent tumor cell killing 
Paper III partly elucidates the mechanism through which anti-MARCO Ab treatment leads to 
reduced tumor growth in the B16 melanoma model. Engagement of MARCO by monoclonal 
Abs results in metabolic re-programming of the immune suppressive macrophages including 
increased glycolysis and HIF-1α expression that is known to be upregulated in pro-
inflammatory macrophages 281,286. Furthermore, targeting scavenger receptor MARCO on 
TAMs activates NK cells to enhance their TRAIL-dependent tumor cell killing. In paper I we 
have shown that engaging MARCO by monoclonal Abs releases extracellular ATP and, in this 
study, we observe that the anti-tumor effect is dependent on ATP-sensing receptor P2X7 
(P2X7R). P2X7R is known to activate the NLRP3 inflammasome 16 but we could not confirm 
any dependency on NLRP3 inflammasome in the anti-MARCO Ab mediated anti-tumor effect 
using NLRP3-deficient mice. Moreover, we discovered that MARCO+ TAMs share 
perivascular TAM markers TIE2 and CXCR4 that are closely located to CD31+ blood vessel. 
TIE2+ TAMs are important for tumor vascularization 225,226 and targeting MARCO by Abs also 
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indicates a reduction in the tortuosity of intra-tumoral CD31+ blood vessels and a trend to less 
branching of vessels. This further supports our findings in paper II that MARCO engagement 
results in macrophage repolarization with decreased tumorigenic features. Pre-clinical 
experiments in the B16 melanoma model revealed anti-MARCO Ab treatment well working 
in line with other immune checkpoint inhibitors anti-PD-1 and anti-PD-L1 Abs. Current 
immune checkpoint therapies have their limits and as some of the melanoma patients only have 
partial responses or do not respond at all we believe that the anti-MARCO Ab therapy can be 
complementary and thus, hopefully increase survival rates and the number of responders. 
Combining anti-MARCO Ab with e.g. anti-PD-1 Ab would target three different immune cell 
types at the same time which makes it a promising approach. Future studies are warranted 
uncovering the exact mechanism that leads to ATP release in the first place and the role of 
P2X7R in the metabolic changes and the induction of anti-tumor responses. Additionally, to 
further increase our understanding of anti-MARCO Ab treatment more experiments are 
required to evaluate the NK cell dependency in other tumor models. 
IV. MARCO is expressed in human PDAC tumors and targeting by antibodies re-
activates human T cells and NK cells that were repressed by tumor- conditioned
medium
In paper IV we showed that MARCO is expressed on myeloid cells in PDAC patients and it is 
correlated with less survival. This study goes in line with paper II and III as we also define 
MARCO to be expressed by immune suppressive cells; however, hypoxia also induces 
MARCO on MDSCs not only TAMs which is shown for the first time. MDSCs and TAMs are 
both known as the most immune suppressive cells within the TME and MDSCs can develop 
into TAMs 287. In contrast to mice, in humans the anti-MARCO Ab mediated effect on T cell 
and NK cell activation is dependent on the NLRP3 inflammasome and subsequent IL-18 
release. Murine and human MARCO are 68% identical 149, thus it is possible that there are 
differences in signal transduction. Moreover, human monocytes are much more sensitive for 
inflammasome activation than mouse cells 288. We detect that IL-10 induces MARCO 
expression, while the blocking of IL-10 reduces it. Targeting IL-10 in the TME has been shown 
to increase anti-tumoral activity by T cells 289; hence, this might be a possibility to convert the 
immune suppressive into a pro-inflammatory TME with increased immune cell infiltration and 
macrophage re-polarization. However, systemic inhibition of IL-10 is not encouraged as this 
also inhibits its effects in inflammatory diseases where IL-10 deals as important anti-
inflammatory modulator. Conventional therapies and T cell-directed immunotherapies have 
failed to treat pancreatic cancer successfully; thus, the anti-hMARCO Ab treatment is a 
promising approach to treat this deathly cancer type. As pancreatic cancers count as “cold” 
tumors with little lymphocyte infiltration 285 it will be important to increase their activity in 
vivo which we achieved with our anti-hMARCO Ab in vitro. Further studies need to be 
implemented addressing differences between mice and humans underlying anti-MARCO 
Ab treatment, such as the dependency on P2X7R signaling. Also, MARCO 
targeted immunotherapy needs to be validated in mouse pancreatic cancer models and 
further in humanized murine models to translate it into humans. 
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